Refine
Has Fulltext
- yes (315)
Year of publication
Document Type
- Journal article (315) (remove)
Language
- English (315) (remove)
Keywords
- ischemic stroke (26)
- Parkinson’s disease (15)
- deep brain stimulation (15)
- multiple sclerosis (15)
- Fabry disease (14)
- neuroinflammation (14)
- Parkinson's disease (12)
- Medizin (11)
- stroke (11)
- inflammation (9)
- neuropathic pain (9)
- pain (8)
- subthalamic nucleus (7)
- B cells (6)
- acute ischemic stroke (6)
- biomarker (6)
- depression (6)
- dopamine (6)
- dystonia (6)
- fibromyalgia syndrome (6)
- mouse model (6)
- neurology (6)
- MS (5)
- antibodies (5)
- blood-brain barrier (5)
- cytokines (5)
- neurodegeneration (5)
- neuroprotection (5)
- traumatic brain injury (5)
- GFAP (4)
- MRI (4)
- blood–brain barrier (4)
- disease (4)
- factor XII (4)
- immunohistochemistry (4)
- macrophages (4)
- magnetic resonance imaging (4)
- mechanical thrombectomy (4)
- middle cerebral artery occlusion (4)
- movement disorders (4)
- mutation (4)
- neuropathy (4)
- platelets (4)
- small fiber neuropathy (4)
- thrombo-inflammation (4)
- tremor (4)
- walking (4)
- COVID-19 (3)
- EAE (3)
- Fabry-associated pain (3)
- Gehirn (3)
- HBMEC (3)
- Mice (3)
- Multiple sclerosis (3)
- Neurodegeneration (3)
- Neuromyelitis optica spectrum disorders (NMOSD) (3)
- Optic neuritis (3)
- Pain (3)
- Parkinson disease (3)
- Ureaplasma parvum (3)
- animal models (3)
- anxiety (3)
- autoantibodies (3)
- basal ganglia (3)
- biomarkers (3)
- brain (3)
- cerebellar tDCS (3)
- cerebral ischemia (3)
- cervical dystonia (3)
- children (3)
- closed head injury (3)
- criteria (3)
- enzyme replacement therapy (3)
- essential tremor (3)
- experimental autoimmune encephalomyelitis (3)
- expression (3)
- gait initiation (3)
- gene expression (3)
- genetics (3)
- inflammasome (3)
- kinematics (3)
- length of stenosis (3)
- local field potentials (3)
- lymphocytes (3)
- macrophage (3)
- mesencephalic locomotor region (3)
- mice (3)
- myelin (3)
- neutrophils (3)
- photothrombotic stroke (3)
- quality of life (3)
- regulatory T cells (3)
- skin punch biopsy (3)
- tMCAO (3)
- therapy (3)
- tight junctions (3)
- transplantation (3)
- trial (3)
- Alzheimer’s disease (2)
- Autoantibodies (2)
- B7-H1 (2)
- Cerebrospinal fluid (2)
- Charcot-Marie-Tooth (2)
- DYT1 (2)
- Diagnosis (2)
- ELISPOT (2)
- Enzyme replacement therapy (2)
- Fabry genotype (2)
- Fabry phenotype (2)
- Fibromyalgia syndrome (2)
- Glatiramer acetate (2)
- Guillain-Barre-Syndrome (2)
- Inflammation (2)
- Longitudinally extensive transverse myelitis (LETM) (2)
- Maus (2)
- Mechanisms (2)
- Myelin oligodendrocyte glycoprotein antibodies (MOG-IgG) (2)
- NEUROWIND (2)
- NLRP3 (2)
- NOAC (2)
- Neuronal ceroid lipofuscinosis (2)
- Neuropathy (2)
- Outcome survey (2)
- PET (2)
- Schlaganfall (2)
- T cells (2)
- T lymphocytes (2)
- T-lymphocytes (2)
- Tourette syndrome (2)
- Treatment (2)
- Ureaplasma urealyticum (2)
- accuracy (2)
- adaptive immune system (2)
- amyotrophic-lateral-sclerosis (2)
- atrial fibrillation (2)
- autoantibody (2)
- base of support (2)
- beta oscillations (2)
- binding (2)
- blood brain barrier (2)
- blood flow (2)
- blood pressure (2)
- c-Fos (2)
- caregiver burden (2)
- carotid atherosclerosis (2)
- carotid stenosis (2)
- carotid ultrasound (2)
- central nervous system (2)
- cerebral autoregulation (2)
- chronic cerebrovascular disease (2)
- chronic pain (2)
- cognitive impairment (2)
- colony-stimulating factor (2)
- contact-kinin system (2)
- degree of stenosis (2)
- dementia (2)
- diagnosis (2)
- differential diagnosis (2)
- disability (2)
- echocardiography (2)
- edema (2)
- electrophysiology (2)
- endoglin (2)
- endothelial cells (2)
- experimental stroke (2)
- fibromyalgia (2)
- gait (2)
- gait analysis (2)
- gene (2)
- generalized cerebral edema (2)
- glial fate modulation (2)
- globotriaosylceramide (2)
- glycoprotein receptor Ib (2)
- guidelines (2)
- hearing loss (2)
- heart failure (2)
- hypoxia (2)
- immune cells (2)
- immunomodulation (2)
- in vivo imaging (2)
- induced pluripotent stem cells (2)
- ion channels (2)
- ischemic penumbra (2)
- lesions (2)
- leukocytes (2)
- major depression (2)
- meningitis (2)
- microRNA (2)
- microglia (2)
- mitochondria (2)
- mortality (2)
- mouse models (2)
- multiple system atrophy (2)
- multiple-sclerosis (2)
- nerve fibers (2)
- neurofilament light chain (2)
- neurons (2)
- opioids (2)
- outcomes (2)
- pathogenesis (2)
- photothrombosis (2)
- polyneuropathy (2)
- predictive value (2)
- protein (2)
- randomized controlled trial (2)
- rat (2)
- relapse (2)
- renal system (2)
- reversible posterior leukoencephalopathy syndrome (2)
- second hit (2)
- spinal cord (2)
- split-belt treadmill (2)
- synaptic vesicles (2)
- thrombosis (2)
- transient ischemic attack (2)
- transient middle cerebral artery occlusion (2)
- velocity (2)
- von Willebrand factor (2)
- 2B (1)
- 3D fluoroscopy (1)
- 5IA-SPECT (1)
- 65-kda isoform (1)
- A-delta fibers (1)
- A53T (1)
- ADHD (1)
- ALS (1)
- ALS mimic (1)
- ALS treatment (1)
- ALSIN gene (1)
- APERIO (1)
- APERIO Hybrid (1)
- ASC (1)
- Adaptive cell transfer (1)
- Adult patients (1)
- Agalsidase beta (1)
- Agalsidase beta therapy (1)
- Alemtuzumab (1)
- Alpha galactosidase (1)
- Alzheimer disease (1)
- Alzheimer’s dementia (1)
- Amplitude (1)
- Amyotrophic Lateral Sclerosis (ALS) (1)
- Amyotrophic Lateral Sclerosis Assessment Questionnaire 5 (ALSAQ-5) (1)
- Anderson-Fabry Disease (1)
- Animal models (1)
- Antibody index (1)
- Antiparanodal Autoantibodies (1)
- Anxiety (1)
- Apoptosis (1)
- Aquaporin-4 antibodies (AQP4-Ig, NMO-IgG)G (1)
- Aquaporin-4 antibodies (AQP4-IgG) (1)
- Aquaporin-4 antibodies (AQP4-IgG, NMO-IgG) (1)
- Arterial Diameters (1)
- Arterial water (1)
- Ataxia (1)
- Atrial fibrillation (1)
- Axon degeneration (1)
- Axonal degeneration (1)
- Azathioprine (1)
- Aδ- and C-fibers (1)
- B-lymphocytes (1)
- BB/OKL rats (1)
- Barkhof criteria (1)
- Beta-glucocerebrosidase (1)
- Biomarker (1)
- Braak (1)
- Brain (1)
- Brain atrophy (1)
- Brain edema (1)
- Brain ischemia (1)
- Brainstem encephalitis (1)
- C.376A>G (p.S126G) (1)
- C1-inhibitor (1)
- C57BL/6 mice (1)
- CCI (1)
- CCS (1)
- CD105 (1)
- CD133 (1)
- CD52 (1)
- CIDP (1)
- CLN3 (1)
- CMV (1)
- CNS (1)
- CNS Myelination (1)
- CNS disease (1)
- CNS imaging (1)
- CNS integrity (1)
- COMPLEX 1 (1)
- COU254 (1)
- CRPS (1)
- CSF (1)
- CSVD (1)
- CXCL4 (1)
- CXCL5 (1)
- CXCL7 (1)
- CXCL8 (1)
- CXCR2 (1)
- Ca2+ homeostasis (1)
- Ca2+ ion analysis (1)
- Ca2+ leak (1)
- Ca2+ oscillation (1)
- Capsaicin receptor (1)
- Caspase (1)
- Cell Index (1)
- Cell therapy (1)
- Cell-based assays (1)
- Cerebellitis (1)
- Cerebral blood flow (1)
- Cerebral small vessel disease (1)
- Cerebral vasospasm (1)
- Cerebral-ischemia (1)
- Charcot-Marie-Tooth disease (1)
- Charcot–Marie–Tooth disease (1)
- Charcot–Marie–Tooth disease type 1A (1)
- CholinomiRs (1)
- Chronic heart failure (1)
- Chronic neuropathic pain (1)
- Cisterna magna (1)
- Clinical manifestations (1)
- Clinically silent stroke (1)
- Coefficient (1)
- Cognitive behavior (1)
- Cognitive decline (1)
- Cold (1)
- Computertomographie (1)
- Corneal confocal microscopy (1)
- Crespi effect (1)
- Cytokines (1)
- D313Y genotype (1)
- DARPA (1)
- DBS biomarkers (1)
- DBS programming (1)
- DOPA-responsive-dystonia (1)
- Deflazacort (1)
- Delphi procedure (1)
- Demyelinating peripheral neuropathy (1)
- Devic’s syndrome (1)
- Diabetes mellitus (1)
- Diabetic polyneuropathy (1)
- Diplopia Internuclear ophthalmoplegia (INO) (1)
- Disease (1)
- Donor lymphocytes (1)
- Dose reduction (1)
- Double hemorrhage model (1)
- Duchenne dystrphy (1)
- Durchblutung (1)
- Dystonia (1)
- EEG data (1)
- ER Ca2+ imaging (1)
- ER Ca2+ store (1)
- ERK1/2 (1)
- Edema (1)
- El Escorial (1)
- Electrophysiology (1)
- English version (1)
- Epilepsy (1)
- EuroQol Five Dimension Five Level Scale (EQ-5D-5L) (1)
- Evoked potentials (1)
- Experimental stroke (1)
- Expression (1)
- F-18-FDG PET (1)
- FOSMN (1)
- FP-CIT SPECT (1)
- FTY720 (1)
- FTY720-P (1)
- FXII (1)
- FXIIa inhibitor rHA-Infestin (1)
- Fabry (1)
- Fabry cardiomyopathy (1)
- Fabry nephropathy (1)
- Facial nerve palsy (1)
- Factor messenger-RNA (1)
- Fc-receptor (1)
- Fibromyalgia (1)
- Fibromyalgie (1)
- Frabin/Fgd4 (1)
- GABAergic neurons (1)
- GCH1 (1)
- GFAP-astrocytopathies (1)
- GRAID (1)
- Gene-expression (1)
- Gland (1)
- Glial fibrillary acidic protein (1)
- Glioblastoma (1)
- Glioma stem cells (1)
- Glutamic-acid decarboxylase anxiety (1)
- Guillain-Barré syndrome (1)
- Guillain-Barré-Syndrom (1)
- HMGB1 (1)
- Head-injury (1)
- Hearing loss (1)
- Heat Hyperalgesia (1)
- Hemodynamic depression (1)
- Hyperalgesia (1)
- IBA-1 (1)
- IL-15 (1)
- IL-22 binding protein isoform (1)
- IL-4 (1)
- IL22RA2 (1)
- IPND criteria (1)
- IVIg (1)
- Identification (1)
- IgG (1)
- Immune system (1)
- Infections (1)
- Innervation (1)
- Insulin (1)
- IntelliCage (1)
- Interferon beta (1)
- Interleukin-18 (1)
- Interleukin-6 (1)
- Interleukin-6-Deficient mice (1)
- International consensus diagnostic criteria for neuromyelitis optica spectrum disorders (1)
- Intractable nausea and vomiting (1)
- Intravascular coagulation (1)
- Ischemia (1)
- Ischemic stroke (1)
- JCV (1)
- K+ channel (1)
- K2P channels (1)
- KCNK5 (1)
- K\(_{2P}\)5.1 (1)
- Kaliumkanal (1)
- L-DOPA (1)
- LI-rTMS (1)
- LIMP-2 (1)
- LSVT-big therapy (1)
- LTD (1)
- Langerhans cells (1)
- Leukemia Inhibitory Factor (1)
- Lewy-like pathology (1)
- Limb girdle muscular dystrophy (LGMD) (1)
- Longitudinally extensive transverse myelitis (1)
- Lysosomal storage disease (1)
- MCC950 (1)
- MDL-28170 (1)
- MIBG scintigraphy (1)
- MIC ligands (1)
- MMP9 (1)
- MOC fibers (1)
- MOG-IgG (1)
- MRI criteria (1)
- MSSS (1)
- Macrophage (1)
- Macrophages (1)
- Magnetic resonance imaging (1)
- Magnetic-resonance (1)
- McDonald criteria (1)
- Mediated Inflammatory Hyperalgesia (1)
- Memory dysfunction (1)
- Meningitis (1)
- Merkel cell density (1)
- Mesenchymal stem/stromal cells (1)
- Methotrexate (1)
- Microglia (1)
- Migräne (1)
- Miyoshi myopathy (1)
- Model (1)
- Molecular-weight heparin (1)
- Monopolar depression (1)
- Motor cortex (1)
- Motor nerve biopsy (1)
- Motor plasticity (1)
- Mucopolysaccharidosis IIIa (1)
- Multiple Sklerose (1)
- Mycobacterium caprae (1)
- Mycobacterium tuberculosis complex (1)
- Myelin oligodendrocyte glycoprotein (MOG) antibodies (1)
- Myelitis (1)
- Myeloma (1)
- NADPH oxidase inhibitors (1)
- NAP-2 (1)
- NETs (1)
- NF-\(\kappa\)B (1)
- NF-κB (1)
- NKG2D (1)
- NKG2D ligands (1)
- NMO-IGG (1)
- NMOSD (1)
- NMR-Tomographie (1)
- NPC1 gene (1)
- NPC2 gene (1)
- NPSI (1)
- Natalizumab (1)
- Necrosis-factor-Alpha (1)
- Nerve growth-factorcopy (1)
- Nestin (1)
- Neuralgie (1)
- Neurogenic inflammation (1)
- Neuroinflammation (1)
- Neuromyelitis optica (NMO) (1)
- Neuromyelitis optica antibodies (NMO-IgG) (1)
- Neurotrophic factors (1)
- Neutrophil (1)
- NfL (1)
- Niemann–Pick disease type C (1)
- Nodo-parandopathy (1)
- OCB (1)
- Ofatumumab (1)
- Oligoclonal bands (1)
- Oncostatin-M-Receptor (1)
- Opioid receptor (1)
- Optical coherence tomography (1)
- Orai2 (1)
- Oral anticoagulation (1)
- Osteopontin (1)
- Outcome (1)
- PD-L1 (1)
- PF4 (1)
- PI3K isoforms (1)
- PML (1)
- PPAR-gamme (1)
- Pain questionnaire (1)
- Pain-related evoked potentials (1)
- Paradoxical heat sensation (1)
- Parkinson (1)
- Parkinsons disease (1)
- Parkionson's disease (1)
- Perfusion (1)
- Peripheral Inflammation (1)
- Peripheral nervous system (1)
- Pharmacological management (1)
- Plasma extravasation (1)
- Pleckstrin homology containing family member 5 (Plekhg5) (1)
- Pointing error (1)
- Pregnancy (1)
- Prodigy (1)
- Progressive supranuclear palsy (1)
- Proprioception (1)
- Quality of life (1)
- R-715 (1)
- RECK (1)
- RKIP (1)
- RNA extraction (1)
- Randomized controlled trial (1)
- Randomized controlled-trial (1)
- Rat (1)
- Rat Sensory Neurons (1)
- Rats (1)
- Receptors (1)
- Regenerative medicine (1)
- Respiratory insufficiency (1)
- Retinal degeneration (1)
- Rheumatoid-Arthritis (1)
- Rho-GTPase Cdc42 (1)
- Rhombencephalitis (1)
- Richardson-Olszewski-Syndrome (1)
- Rituximab (1)
- Rochester diabetic neuropathy (1)
- SARS-CoV (1)
- SB332235 (1)
- SERCA (1)
- SHRSP (1)
- SNI (1)
- SOD1 mutations (1)
- SPG4 (1)
- SREBP (1)
- STAIR (1)
- STEMI (1)
- Schwann cell (1)
- Schwann cell dedifferentiation (1)
- Schwann cell differentiation (1)
- Schwann-cells (1)
- Screening questionnaire (1)
- Secondary stroke prevention (1)
- Sensitivity (1)
- Serotonin (1)
- Silver-syndrome (1)
- Sjorgens-syndrome (1)
- Skelettmuskel (1)
- Skin biopsy (1)
- Small fiber dysfunction (1)
- Small fiber neuropathy (1)
- Small-fiber neuropathy (1)
- Sonic hedgehog (1)
- Sphingosine 1-Phosphate (1)
- Stim (1)
- Stimuli (1)
- Stroke (1)
- Stroke unit (1)
- Subarachnoid (1)
- Subarachnoid hemorrhage (1)
- Survey (1)
- System involvement (1)
- T cell activation (1)
- T-PA (1)
- T-cells (1)
- TASK2 (1)
- TBI (1)
- TDMT (1)
- TIMP-1 (1)
- TIND (1)
- TLO (1)
- TMS (1)
- TNF-α (1)
- TNFα (1)
- TOR1A (1)
- TRP Channels (1)
- TSPO (1)
- Tdp-43 (1)
- Therapy (1)
- Thermal Hyperalgesia (1)
- Thrombus (1)
- Thrombus formation (1)
- Training (1)
- Transverse Myelitis (1)
- Transverse myelitis (1)
- Tryptophan hydroxylase-2 (Tph2) (1)
- Tuberkulose (1)
- Type 1 diabetes (1)
- Ureaplasma species (1)
- VCAM-1 (1)
- Vaccination (1)
- Vasodilatator-stimuliertes Phosphoprotein (1)
- Vasodilator-Stimulated Phosphoprotein (1)
- Von-Willebrand-factor (1)
- Western blot (1)
- Wingerchuk criteria 2006 and 2015 (1)
- X-chromosomal inactivation (1)
- XAV-939 (1)
- Zonula Occludens-1 (1)
- [18F]FDG positron emission tomography (1)
- acid sphingomyelinase (1)
- activation (1)
- acute lymphoblastic leukaemia (1)
- acute management of stroke (1)
- acute neurology (1)
- acute stroke imaging (1)
- acute stroke management (1)
- acute stroke outcome (1)
- adhesion molecules (1)
- adrenal medulla (1)
- adult-onset (1)
- advanced therapy medicinal products (1)
- afferents (1)
- age (1)
- aggression (1)
- aging (1)
- albumin (1)
- algorithm (1)
- alias pilot trial (1)
- allodynia (1)
- alpha-7 nicotinic acetylcholine receptor (1)
- alpha-galactosidase A (1)
- alpha‐synuclein (1)
- alpha‐synuclein propagation (1)
- alpha‐synuclein seeding (1)
- amygdala (1)
- amyotrophic lateral sclerosis (1)
- amyotrophic lateral sclerosis (ALS) (1)
- analgesia (1)
- analgesic medication (1)
- aneurysm surgery (1)
- angiography (1)
- animal behavior (1)
- animal model (1)
- ankles (1)
- antagomir (1)
- anthropometric measurement (1)
- anthropometric measurements (1)
- anti-aquaporin-4 antibody (1)
- anti-contactin-1 (1)
- anticoagulants (1)
- anticoagulation (1)
- antidepressants (1)
- apoE (1)
- apoe (1)
- apomorphine (1)
- aquaporin 4 (1)
- aquaporin-4 autoantibodies (1)
- areas (1)
- arm (1)
- artery occlusion (1)
- assistive devices (1)
- association (1)
- association studies in genetics (1)
- astrocyte (1)
- astrocytes (1)
- astrogliosis (1)
- atherosclerosis (1)
- atrophy Kennedys-disease (1)
- attention deficit/hyperactivity disorder (ADHD) (1)
- attenuation of disease (1)
- atypical chemokine receptor 3 (1)
- autoantibody (aAb) (1)
- autoimmune (1)
- autoimmune neuroinflammation (1)
- autophagy (1)
- autoradiography (1)
- axonal degeneration (1)
- axonal integrity (1)
- axonal transcriptome (1)
- axonal transport (1)
- axonopathic changes (1)
- back pain (1)
- balance (1)
- barrier (1)
- barrier integrity (1)
- basal forebrain cholinergic neurons (1)
- behavioral disorders (1)
- beta oscillation (1)
- beta power (1)
- bilateral internal carotid artery stenosis (1)
- binding analysis (1)
- biological locomotion (1)
- biopsies (1)
- biopsy (1)
- blood (1)
- blood coagulability (1)
- blood coagulation (1)
- blood nerve barrier (1)
- bone-marrow (1)
- botulinum toxin (1)
- bradykinesia (1)
- bradykinin (1)
- brain dynamics (1)
- brain edema (1)
- brain endothelium (1)
- brain metabolic alterations (1)
- brain networks (1)
- brain state (1)
- brain stem (1)
- burning pain (1)
- calpain (1)
- capsaicin (1)
- cardiac imaging (1)
- cardiac magnetic resonance imaging (1)
- cardiovascular disease (1)
- care (1)
- care tempis (1)
- caregiver (1)
- case report (1)
- caudate nucleus (1)
- celiac disease (1)
- cell adhesion (1)
- cell binding assay (1)
- cellular therapy (1)
- cerebellar vermis hypoplasia (1)
- cerebellum (1)
- cerebral arteries (1)
- cerebral blood flow (1)
- cerebral microbleeds (1)
- cerebral small vessel disease (1)
- cerebrospinal fluid (1)
- cerebrospinal fluid culture (1)
- cerebrospinal-fluid (1)
- cerebrovascular diseases (1)
- cerebrovascular disorders (1)
- chemokines (1)
- chitinase-3-like protein 1 (1)
- choline acetyltransferase (1)
- cholinergic activity (1)
- cholinergic system (1)
- chronic constriction nerve injury (CCI) (1)
- chronic kidney disease (1)
- chronic stimulation (1)
- chronic stress (1)
- classification (1)
- claudin-1 (1)
- clinical approach (1)
- clinical diagnosis (1)
- clinical neurology (1)
- clinical outcome (1)
- clinical phenotype (1)
- clip control (1)
- closed-loop (1)
- coagulation (1)
- coagulation factor XIIa (1)
- cochlea (1)
- cognitive (1)
- cognitive decline (1)
- cognitive function (1)
- coherence (1)
- coherence analysis (1)
- collagens (1)
- collateral circulation (1)
- colony stimulating factor 1 (1)
- compensatory strategies (1)
- complement (1)
- complement deposition (1)
- comprehension (1)
- computed tomography (1)
- computer vision (1)
- consolidation (1)
- contact activation system (1)
- continuous theta burst stimulation (cTBS) (1)
- contrast (1)
- contrast-enhanced MRI (1)
- conversion (1)
- coordination (1)
- coping (1)
- corneal confocal microscopy (1)
- cortical activation (1)
- cortical excitability (1)
- cortical oscillatory activity (1)
- cortical pathology (1)
- cortical silent period (1)
- crossover trial (1)
- cue (1)
- cutaneous innervation (1)
- cutaneous patch (1)
- cutting edge (1)
- damage cool aid (1)
- darbepoetin alpha (1)
- data filtering (1)
- decreasing autonomy (1)
- deep brain stimulation (DBS) (1)
- deep brain-stimulation (1)
- degeneration (1)
- delayed cerebral infarction (1)
- delays progression (1)
- demography (1)
- demyelinating disease (1)
- demyelinating polyradiculoneuropathy (1)
- demyelination (1)
- dendric cells (1)
- design (1)
- developmental signaling (1)
- diabetes mellitus (1)
- diabetic neuropathy (1)
- diagnosis in Fabry disease (1)
- diagnostic delay (1)
- diagnostic markers (1)
- diagnostic medicine (1)
- diagnostics (1)
- diffuse (1)
- digital medicine (1)
- dimethyl fumarate (1)
- directional deep brain stimulation (1)
- disease model (1)
- disease progression (1)
- disease severity (1)
- disease-modifying therapy (1)
- disorder (1)
- domain potassium channels (1)
- dopamine acetylcholine (1)
- dopamine transporter (DAT) (1)
- drug (1)
- duodenal levodopa infusion (1)
- dysferlinopathy (1)
- edoxaban (1)
- effects (1)
- efficacy (1)
- ejection fraction (1)
- electromyography (1)
- element (1)
- embolic stroke (1)
- emulsions (1)
- encephalitis (1)
- endothelin-1 (1)
- endotheliopathy (1)
- enteropathy (1)
- enzyme assays (1)
- enzyme-linked immunoassays (1)
- epidermis (1)
- event-related desynchronization (1)
- exercise (1)
- exome sequencing (1)
- experimental (1)
- experimental autoimmune neuritis (1)
- experimental design (1)
- expert opinion (1)
- extensiv transverse myelitis (1)
- eye movement disorders (1)
- facial pain (1)
- factor XI (1)
- familial amyloidotic polyneuropathy (1)
- family caregiver (1)
- fatigue (1)
- fear (1)
- fear memory (1)
- feasibility (1)
- female Fabry patients (1)
- females (1)
- fibers (1)
- fibroblast (1)
- finger-tapping task (1)
- fingolimod (1)
- flotillin-1 lipid rafts (1)
- fluorine (1)
- focal (1)
- focal brain lesion (1)
- focal cerebral ischemia (1)
- focal cerebral-ischemia (1)
- fosfomycin (1)
- free radical scavenger (1)
- freezing of gait (1)
- freezing of gait (FOG) (1)
- fullerenes (1)
- functional MRI (1)
- functional neuroanatomy (1)
- functional status (1)
- fungal infection (1)
- future directions (1)
- gadofluorine (1)
- gadolinium-DTPA (1)
- gait modulation (1)
- gait-phase prediction (1)
- galactomannan (1)
- gender (1)
- gene mutations (1)
- gene variant (1)
- gene-by-environment interaction (1)
- gene-environment interaction (1)
- generalized cerebellar atrophy (1)
- genome-wide association study (1)
- genotype-phenotype correlation (1)
- genotype/phenotype correlation (1)
- gephyrin (1)
- glial damage (1)
- glial fibrillary acidic protein (1)
- glioblastoma multiforme (1)
- globus pallidus (1)
- globus pallidus pars interna (GPi) (1)
- glycation end products (1)
- glycine receptor (1)
- glycine receptor (GlyR) (1)
- glycine receptor autoantibodies (1)
- glycoprotein Ib (1)
- glycoprotein VI (1)
- glycoprotein receptor Ibα (1)
- granzyme B (1)
- gridle muscular-dystrophy (1)
- growth (1)
- growth pattern (1)
- health behavior (1)
- health-related quality of life (1)
- health-related quality of life (HRQoL) (1)
- hemicraniectomy (1)
- hemorrhagic transformation (1)
- hereditary motor and sensory neuropathy (1)
- hereditary spastic paraplegia (HSP) (1)
- hernia repair (1)
- hexanucleotide repeat (1)
- high contrast (1)
- hip (1)
- hippocampus (1)
- histology (1)
- homotypic fusion and protein sorting (1)
- hospitals (1)
- human brain endothelium (1)
- human brain microvascular endothelial cells (1)
- human cerebral endothelial cells (1)
- human muscle-cells (1)
- human neurons (1)
- humans (1)
- hyperalgesia (1)
- hypercholesterolemia (1)
- hyperekplexia (1)
- hypothermia (1)
- i.v. thrombolysis (1)
- idiopathic inflammatory myopathies (1)
- image quality (1)
- image-guided programming (1)
- imaging (1)
- immaturity (1)
- immune (1)
- immune system (1)
- immune-response (1)
- immunofluorescence (1)
- immunoglobulin-G (1)
- in-vivo (1)
- incidence (1)
- increased risk (1)
- induced neural stem cells (1)
- inducible expression (1)
- inertial measurement units (1)
- infantile neuronal ceroid lipofuscinosis (1)
- infarction (1)
- infarction size (1)
- infarction volume (1)
- inflammatory cascades (1)
- inflammatory demyelinating polyradiculoneuropathy (1)
- inflammatory neuropathy (1)
- informal care (1)
- informal caregiving (1)
- informed consent (1)
- inherited metabolic disorders (1)
- inherited peripheral neuropathy (1)
- injection site reactions; (1)
- innate immune system (1)
- innervation (1)
- integrin α2 (1)
- integrins (1)
- interference (1)
- interleukin-1 receptor antagonist (1)
- interleukin-8 (1)
- internal carotid artery stenosis (1)
- internet-based intervention (1)
- interval timing (1)
- interview (1)
- intracranial bleeding (1)
- intracranial hemorrhage (1)
- intractable hiccup (1)
- intraepidermal nerve fiber density (1)
- intraepidermal nerve fibre density (1)
- intraoperative (1)
- intrathecal application (1)
- intravenous immunoglobulin (1)
- intravenous thrombolysis (1)
- invasive electric stimulation (1)
- iron (1)
- iron dyshomeostasis (1)
- iron oxide nanoparticles (1)
- ischemia (1)
- ischemia/reperfusion injury (1)
- ischemic cascade (1)
- just noticeable difference (JND) (1)
- kallikrein-kinin system (1)
- kallikrein–kinin system (1)
- kinesthesia (1)
- kinin receptor (1)
- kinin receptors (1)
- knees (1)
- large vessel occlusion (1)
- learning (1)
- levodopa-induced dyskinesia (1)
- linkage (1)
- liponeurocytoma (1)
- locomotion (1)
- locomotor adaptation (1)
- locus coeruleus (1)
- long-term pain (1)
- lymphokine-activated killer (1)
- lyso-Gb3 (1)
- lysosomal dysfunction (1)
- lysosomal enzyme (1)
- lysosomal storage disease (1)
- lyso‐Gb3 (1)
- machine learning (1)
- magnesium (1)
- management (1)
- matrix metalloproteinases (1)
- mechanical energy (1)
- mechanisms (1)
- medial ganglionic eminence (1)
- medulloblastoma (1)
- mental health (1)
- mesenchymal stem and stromal cells (1)
- mesenchymal stem cells (1)
- metaanalysis (1)
- methylphenidate (1)
- miR-182-5p (1)
- miR-21 (1)
- miRNA (1)
- miRNA expression patterns (1)
- miRNA polymorphisms (1)
- miRNA-based analgesic (1)
- miRNA-based diagnostics (1)
- mice impact (1)
- microangiopathy (1)
- microsphere/macrosphere (1)
- microtubules (1)
- midbrain (1)
- migraine (1)
- migraineur (1)
- mixed fiber neuropathy (1)
- mixed methods (1)
- molecular signature (1)
- monocycline (1)
- monocytes (1)
- monomethyl fumarate (1)
- motoneuron disease (1)
- motor (1)
- motor axonal neuropathy (1)
- motor control (1)
- motor cortex (1)
- motor evoked potential (MEP) (1)
- motor function (1)
- motor learning (1)
- motor neuron disease (1)
- motor neuropathy (1)
- motor proteins (1)
- motor-evoked potentials (MEP) (1)
- mouse (1)
- mouse brain microvascular endothelial cell cultur (1)
- movement (1)
- movements (1)
- multiple sklerosis (1)
- muscle atrophy (1)
- muscle strength (1)
- musical syntax (1)
- musk myasthenia gravis (1)
- myasthenia gravis (1)
- myelination (1)
- myocardial infarction (1)
- natural history (1)
- near-infrared spectroscopy (1)
- neonatal meningitis (1)
- nerve biopsy (1)
- nerve fibres (1)
- nerve tumor (1)
- nerve-fibers (1)
- nervous system (1)
- nervous-system (1)
- neural apoptosis (1)
- neural stem cell (1)
- neural stem cells (1)
- neuralgia (1)
- neurobehavioural deficits (1)
- neuroborreliosis (1)
- neurocritical care (1)
- neurocytoma (1)
- neurofascin (1)
- neurofilaments (1)
- neuroleukemiosis (1)
- neurological complications (1)
- neurological examination (1)
- neuromelanin (1)
- neuronal apoptosis (1)
- neuronal differentiation (1)
- neuronal network (1)
- neuronal stem cells (1)
- neuronopathy (1)
- neurophysiology (1)
- neuroplasticity (1)
- neurorepair (1)
- neutrophil (1)
- nicotinamide (1)
- nicotinic receptors (1)
- nociceptor sensitization (1)
- nodes of Ranvier (1)
- non-motor features (1)
- nonalcoholic steatohepatitis (1)
- noradrenalin (1)
- norepinephrine (1)
- novo renal transplantation (1)
- nucleus ventralis intermedius (1)
- nystagmus (1)
- object recognition memory (1)
- obstacle avoidance (1)
- occlusion (1)
- oligodendroglia (1)
- online systems (1)
- ontactin 1 (1)
- opioid (1)
- optical coherence tomography (1)
- outcome (1)
- outer hair cell (OHC) (1)
- oxidative stress (1)
- p.R245H (1)
- p.S298P (1)
- p38 mitogen-activated protein kinase (1)
- p57kip2 (1)
- pain pattern (1)
- pain questionnaire (1)
- pain sensation (1)
- pain-associated behavior (1)
- pain-related evoked potentials (1)
- pallidal stimulation (1)
- pandemic (1)
- paranodopathy (1)
- paraparesis (1)
- parkinson disease (1)
- parkinsons disease (1)
- passive transfer (1)
- pathology section (1)
- pathophysiology (1)
- pathway analysis (1)
- pathways (1)
- patient reported outcome measures (1)
- patient triage (1)
- pedunculopontine nucleus (PPN) (1)
- pegylated insulin-like growth factor 1 (1)
- peptide (1)
- periperal nerve (1)
- peripheral injury (1)
- peripheral nerve involvement (1)
- peripheral nervous system (1)
- peripheral nervous-system (1)
- peripheral neuropathy (1)
- permanent and transient middle cerebral artery occlusion (1)
- pet (1)
- ph (1)
- phosphorylated tau protein (1)
- physical activity (1)
- physical therapy modalities (1)
- pilot project (1)
- placebo-controlled (1)
- plaque cross-sectional area (1)
- plasma extravasation (1)
- plasma oxysterols (1)
- plasminogen (1)
- platelet activation (1)
- platelet aggregation (1)
- point-of-care echocardiography (1)
- pointing task (1)
- polymorphism (1)
- polymorphisms inflammation (1)
- polymyositis (1)
- position estimation (1)
- post-processing (1)
- post-traumatic stress disorder (1)
- postherpetic neuralgia (1)
- postural control (1)
- posture (1)
- potassium channels (1)
- potent inducer (1)
- precision medicine (1)
- preclinical research (1)
- prednisone (1)
- prefrontal cortex (1)
- presynaptic inhibition (1)
- preterm birth (1)
- preventive treatment (1)
- prognosis (1)
- progression (1)
- progressive ataxia (1)
- progressive encephalitis with rigidity and myoclonus (PERM) (1)
- progressive supranuclear palsy (1)
- proinflammatory cytokine (1)
- protein and mRNA expression (1)
- proteins (1)
- proteolipid protein (1)
- proteolipid protein gene (1)
- proteomics (1)
- psychological support (1)
- psychophysics (1)
- purmorphamine (1)
- quality (1)
- quality of life (QoL) (1)
- quality-control (1)
- quantitative sensory testing (1)
- qutenza (1)
- randomized controlled double-blind study (1)
- rat brain microvascular endothelial cell culture (1)
- rat hepatocytes (1)
- rats (1)
- reach-to-grasp movement (1)
- reaction-time tasks (1)
- receptor (1)
- receptor tyrosine kinase (1)
- recombinant tissue-type plasminogen activator (1)
- recommendations (1)
- recurrence (1)
- reflex (1)
- regional heterogeneity (1)
- regulation (1)
- regulatory cells (1)
- rehabilitation (1)
- reinnervation (1)
- relapsing multiple sclerosis (1)
- relapsing-remitting multiple sclerosis (1)
- religiosity (1)
- renal function (1)
- reoxygenation (1)
- reperfusion (1)
- reperfusion injury (1)
- reproducible outcome measure (1)
- responsivity (1)
- resting tremor (1)
- retinal ganglion cells (1)
- retinocochleocerebral (1)
- rett (1)
- rhythm perception (1)
- risk (1)
- risk factors (1)
- risk of fall (1)
- rt-PA (1)
- scale (1)
- sciatic nerve (1)
- sciatic nerves (1)
- search filter (1)
- secondary infarct growth (1)
- secretome (1)
- segmental centers of mass (1)
- sensory neurons (1)
- serotonin (1)
- serum (1)
- sex addiction (1)
- shedding (1)
- shingles (1)
- signal peptide (1)
- single photon emission computed tomography (SPECT) (1)
- skilled forelimb movements (1)
- skin biopsy (1)
- skin diseases (1)
- skin tumors (1)
- small vessel disease (1)
- small-fiber neuropathy (1)
- socioeconomic status (1)
- soleus muscles (1)
- soluble endoglin (1)
- somatosensory temporal discrimination (1)
- somatosensory-evoked-potentials (1)
- sphingolipids (1)
- spinal cord injury (1)
- spinal muscular atrophy (1)
- spinal-cord (1)
- spinal-cord-injury (1)
- startle disease (1)
- stent-retriever device (1)
- steroids (1)
- stiff-person syndrome (SPS) (1)
- stimulation (1)
- store-operated Ca2+ entry (1)
- stress (1)
- striatum (1)
- stroke care (1)
- stroke unit (1)
- stromal cells (1)
- study (1)
- subarachnoid hemorrhage (1)
- subcutaneous injection (1)
- substance-P (1)
- subthalamic nucleus (STN) (1)
- swimming (1)
- switch (1)
- symptom-specific treatment (1)
- synapse (1)
- synaptic transmission (1)
- syndrome (1)
- system (1)
- systematic review (1)
- systems biology (1)
- systolic dysfunction (1)
- target considerations (1)
- task retention (1)
- telemedicine (1)
- telemedicine network (1)
- temporal discrimination threshold (1)
- teriflunomide (1)
- term follow-up (1)
- tetrahydroisoquinoline derivates (1)
- tetraparesis (1)
- thrombemboli (1)
- thromboemboli (1)
- thromboembolic clot model (1)
- thromboembolic stroke (1)
- thromboinflammation (1)
- thrombolysis (1)
- thrombus formation (1)
- tics (1)
- time (1)
- time perception (1)
- timing (1)
- tissue-plasminogen activator (1)
- tool (1)
- topography (1)
- torsinA (1)
- transcranial direct current stimulation (1)
- transcranial magnetic simulation (TMS) (1)
- transgenic mouse model (1)
- transient middle cerebral artery (1)
- transient receptor potential vanilloid 1 (TRPV1) (1)
- translation (1)
- translational research (1)
- translational stroke research (1)
- transmission electron microscopy (1)
- treatment options (1)
- treatment-induced neuropathy in diabetes (TIND) (1)
- treatment-resistant depression (1)
- trigeminal nerve (1)
- trigeminal neuropathy (1)
- troponin (1)
- tuberculous meningitis (1)
- tumor immunity (1)
- ultrasound imaging (1)
- under-dosing (1)
- up-regulation (1)
- validation (1)
- variants of unknown significance (1)
- vascular dementia (1)
- vascular homeostasis (1)
- vascular permeability (1)
- vasculopathy (1)
- vertebrobasilar insufficiency (1)
- vertigo (1)
- vessel patency (1)
- vestibular (1)
- videooculography (1)
- virtual reality (1)
- visual activity (1)
- visual pathways (1)
- volume regulation (1)
- voluntary movement (1)
- weight drop (1)
- white blood cells (1)
- white matter hyperintensities (1)
- white matter lesions (1)
- α-Galactosidase A (1)
- α-synuclein (1)
- α-synuclein-specific T cells (1)
- α‐GalA 3D‐structure (1)
- β-APP (1)
- “bulbar-onset” ALS (bALS) (1)
- “limb-onset” ALS (lALS) (1)
Institute
- Neurologische Klinik und Poliklinik (315) (remove)
Sonstige beteiligte Institutionen
- Datenintegrationszentrum Würzburg (DIZ) (1)
- Interdisziplinäre Biomaterial- und Datenbank Würzburg (ibdw) (1)
- Klinische Studienzentrale (Universitätsklinikum) (1)
- Wurzburg Fabry Center for Interdisciplinary Therapy (FAZIT), Wurzburg, Germany (1)
- Würzburg Fabry Center for Interdisciplinary Therapy (FAZIT), University of Würzburg, Würzburg, Germany (1)
Background
Postherpetic neuralgia (PHN) is the painful complication of a varicella zoster virus reactivation. We investigated the systemic and local gene expression of pro- and anti-inflammatory cytokine expression in patients with PHN.
Methods
Thirteen patients with PHN at the torso (Th4-S1) were recruited. Skin punch biopsies were obtained from the painful and the contralateral painless body area for intraepidermal nerve fiber density (IENFD) and cytokine profiling. Additionally, blood was withdrawn for systemic cytokine expression and compared to blood values of healthy controls. We analyzed the gene expression of selected pro- and anti-inflammatory cytokines (tumor necrosis factor-alpha [TNF] and interleukins [IL]-1β, IL-2, and IL-8).
Results
IENFD was lower in affected skin compared to unaffected skin (p<0.05), while local gene expression of pro- and anti-inflammatory cytokines did not differ except for two patients who had 7fold higher IL-6 and 10fold higher IL-10 gene expression in the affected skin compared to the contralateral unaffected skin sample. Also, the systemic expression of cytokines in patients with PHN and in healthy controls was similar.
Conclusion
While the systemic and local expression of the investigated pro- and anti-inflammatory cytokines was not different from controls, this may have been influenced by study limitations like the low number of patients and different disease durations. Furthermore, other cytokines or pain mediators need to be considered.
Interleukin-4 (IL-4) is an anti-inflammatory and analgesic cytokine that induces opioid receptor transcription. We investigated IL-4 knockout (ko) mice to characterize their pain behavior before and after chronic constriction injury (CCI) of the sciatic nerve as a model for neuropathic pain. We investigated opioid responsivity and measured cytokine and opioid receptor gene expression in the peripheral and central nervous system (PNS, CNS) of IL-4 ko mice in comparison with wildtype (wt) mice. Naïve IL-4 ko mice displayed tactile allodynia (wt: 0.45 g; ko: 0.18 g; p<0.001), while responses to heat and cold stimuli and to muscle pressure were not different. No compensatory changes in the gene expression of tumor necrosis factor-alpha (TNF), IL-1β, IL-10, and IL-13 were found in the PNS and CNS of naïve IL-4 ko mice. However, IL-1β gene expression was stronger in the sciatic nerve of IL-4 ko mice (p<0.001) 28 days after CCI and only IL-4 ko mice had elevated IL-10 gene expression (p = 0.014). Remarkably, CCI induced TNF (p<0.01), IL-1β (p<0.05), IL-10 (p<0.05), and IL-13 (p<0.001) gene expression exclusively in the ipsilateral spinal cord of IL-4 ko mice. The compensatory overexpression of the anti-inflammatory and analgesic cytokines IL-10 and IL-13 in the spinal cord of IL-4 ko mice may explain the lack of genotype differences for pain behavior after CCI. Additionally, CCI induced gene expression of μ, κ, and δ opioid receptors in the contralateral cortex and thalamus of IL-4 ko mice, paralleled by fast onset of morphine analgesia, but not in wt mice. We conclude that a lack of IL-4 leads to mechanical sensitivity; the compensatory hyperexpression of analgesic cytokines and opioid receptors after CCI, in turn, protects IL-4 ko mice from enhanced pain behavior after nerve lesion.
High-Dose Capsaicin for the Treatment of Neuropathic Pain: What We Know and What We Need to Know
(2014)
Neuropathic pain is a frequent and disabling condition with diverse underlying etiologies and is often difficult to treat. Systemic drug treatment is often limited in efficacy. Furthermore, adverse effects may be a limiting factor when trying to reach the necessary dose. Analgesics that can be applied topically have the potential to largely overcome this problem. They may be of particular advantage in localized neuropathic pain syndromes such as postherpetic neuralgia or small fiber neuropathy. Capsaicin, the pungent component of chili peppers, is a natural ligand of the transient receptor potential vanilloid 1 channel and has long been used as topically applicable cream with concentrations of 0.025 to 0.075%. In 2009, a high-concentration transdermal capsaicin 8% patch (Qutenza ; Acorda Therapeutics, Inc., Ardsley, NY, USA; Astellas Pharma Europe Ltd., Chertsey, Surrey, UK) was introduced for the treatment of peripheral neuropathic pain syndromes other than of diabetic origin in adults. It has since been widely used in diverse neuropathic pain disorders. In this review article, we summarize current knowledge on Qutenza, its advantages and problems, and expose unmet needs.
Background
The X-chromosomally linked life-limiting Fabry disease (FD) is associated with deposits of the sphingolipid globotriaosylceramide 3 (Gb3) in various tissues. Skin is easily accessible and may be used as an additional diagnostic and follow-up medium. Our aims were to visualize skin Gb3 deposits in FD patients applying immunofluorescence and to determine if cutaneous Gb3 load correlates with disease severity.
Methods
At our Fabry Center for Interdisciplinary Therapy we enrolled 84 patients with FD and 27 healthy controls. All subjects underwent 5-mm skin punch biopsy at the lateral lower leg and the back. Skin samples were processed for immunohistochemistry using antibodies against CD77 (i.e. Gb3). Cutaneous Gb3 deposition was quantified in a blinded manner and correlated to clinical data.
Results
We found that Gb3 load was higher in distal skin of male FD patients compared to healthy controls (p<0.05). Men (p<0.01) and women (p<0.05) with a classic FD phenotype had higher distal skin Gb3 load than healthy controls. Men with advanced disease as reflected by impaired renal function, and men and women with small fiber neuropathy had more Gb3 deposits in distal skin samples than males with normal renal function (p<0.05) and without small fiber neuropathy. Gb3 deposits were not different between patients with and without enzyme replacement therapy.
Conclusions
Immunofluorescence on minimally invasive skin punch biopsies may be useful as a tool for assessment and follow-up in FD patients.
Objectives
The pathogenesis of fibromyalgia syndrome (FMS) is unclear. Transcranial ultrasonography revealed anechoic alteration of midbrain raphe in depression and anxiety disorders, suggesting affection of the central serotonergic system. Here, we assessed midbrain raphe echogenicity in FMS.
Methods
Sixty-six patients underwent transcranial sonography, of whom 53 were patients with FMS (27 women, 26 men), 13 patients with major depression and physical pain (all women), and 14 healthy controls (11 women, 3 men). Raphe echogenicity was graded visually as normal or hypoechogenic, and quantified by digitized image analysis, each by investigators blinded to the clinical diagnosis.
Results
Quantitative midbrain raphe echogenicity was lower in patients with FMS compared to healthy controls (p<0.05), but not different from that of patients with depression and accompanying physical pain. Pain and FMS symptom burden did not correlate with midbrain raphe echogenicity as well as the presence and severity of depressive symptoms.
Conclusion
We found reduced echogenicity of the midbrain raphe area in patients with FMS and in patients with depression and physical pain, independent of the presence or severity of pain, FMS, and depressive symptoms. Further exploration of this sonographic finding is necessary before this objective technique may enter diagnostic algorithms in FMS and depression.
Background
Fibromyalgia syndrome (FMS) is a chronic condition characterized by widespread pain and associated symptoms. We investigated cerebral activation in FMS patients by functional near-infrared spectroscopy (fNIRS).
Methods
Two stimulation paradigms were applied: a) painful pressure stimulation at the dorsal forearm; b) verbal fluency test (VFT). We prospectively recruited 25 FMS patients, ten patients with unipolar major depression (MD) without pain, and 35 healthy controls. All patients underwent neurological examination and all subjects were investigated with questionnaires (pain, depression, FMS, empathy).
Results
FMS patients had lower pressure pain thresholds than patients with MD and controls (p < 0.001) and reported higher pain intensity (p < 0.001). Upon unilateral pressure pain stimulation fNIRS recordings revealed increased bilateral cortical activation in FMS patients compared to controls (p < 0.05). FMS patients also displayed a stronger contralateral activity over the dorsolateral prefrontal cortex in direct comparison to patients with MD (p < 0.05). While all three groups performed equally well in the VFT, a frontal deficit in cortical activation was only found in patients with depression (p < 0.05). Performance and cortical activation correlated negatively in FMS patients (p < 0.05) and positively in patients with MD (p < 0.05).
Conclusion
Our data give further evidence for altered central nervous processing in patients with FMS and the distinction between FMS and MD.
Skin cytokine expression in patients with fibromyalgia syndrome is not different from controls
(2014)
Background
Fibromyalgia syndrome (FMS) is a chronic pain syndrome of unknown etiology. There is increasing evidence for small nerve fiber impairment in a subgroup of patients with FMS. We investigated whether skin cytokine and delta opioid receptor (DOR) gene expression in FMS patients differs from controls as one potential contributor to small nerve fiber sensitization.
Methods
We investigated skin punch biopsies of 25 FMS patients, ten patients with monopolar depression but no pain, and 35 healthy controls. Biopsies were obtained from the lateral upper thigh and lower calf. Gene expression of the pro-inflammatory cytokines tumor necrosis factor-alpha (TNF), interleukin (IL)-6, and IL-8 and of the anti-inflammatory cytokine IL-10 was analyzed using quantitative real-time PCR and normalizing data to 18sRNA as housekeeping gene. Additionally, we assessed DOR gene expression.
Results
All cytokines and DOR were detectable in skin samples of FMS patients, patients with depression, and healthy controls without intergroup difference. Also, gene expression was not different in skin of the upper and lower leg within and between the groups and in FMS patient subgroups.
Conclusions
Skin cytokine and DOR gene expression does not differ between patients with FMS and controls. Our results do not support a role of the investigated cytokines in sensitization of peripheral nerve fibers as a potential mechanism of small fiber pathology in FMS.
Background
Fabry disease is an inborn lysosomal storage disorder which is associated with small fiber neuropathy. We set out to investigate small fiber conduction in Fabry patients using pain-related evoked potentials (PREP).
Methods
In this case–control study we prospectively studied 76 consecutive Fabry patients for electrical small fiber conduction in correlation with small fiber function and morphology. Data were compared with healthy controls using non-parametric statistical tests. All patients underwent neurological examination and were investigated with pain and depression questionnaires. Small fiber function (quantitative sensory testing, QST), morphology (skin punch biopsy), and electrical conduction (PREP) were assessed and correlated. Patients were stratified for gender and disease severity as reflected by renal function.
Results
All Fabry patients (31 men, 45 women) had small fiber neuropathy. Men with Fabry disease showed impaired cold (p < 0.01) and warm perception (p < 0.05), while women did not differ from controls. Intraepidermal nerve fiber density (IENFD) was reduced at the lower leg (p < 0.001) and the back (p < 0.05) mainly of men with impaired renal function. When investigating A-delta fiber conduction with PREP, men but not women with Fabry disease had lower amplitudes upon stimulation at face (p < 0.01), hands (p < 0.05), and feet (p < 0.01) compared to controls. PREP amplitudes further decreased with advance in disease severity. PREP amplitudes and warm (p < 0.05) and cold detection thresholds (p < 0.01) at the feet correlated positively in male patients.
Conclusion
Small fiber conduction is impaired in men with Fabry disease and worsens with advanced disease severity. PREP are well-suited to measure A-delta fiber conduction.
A high load of white matter lesions and enlarged basilar arteries have been shown in selected patients with Fabry disease, a disorder associated with an increased stroke risk. We studied a large cohort of patients with Fabry disease to differentially investigate white matter lesion load and cerebral artery diameters. We retrospectively analyzed cranial magnetic resonance imaging scans of 87 consecutive Fabry patients, 20 patients with ischemic stroke, and 36 controls. We determined the white matter lesion load applying the Fazekas score on fluid-attenuated inversion recovery sequences and measured the diameters of cerebral arteries on 3D-reconstructions of the time-of-flight-MR-angiography scans. Data of different Fabry patient subgroups (males – females; normal – impaired renal function) were compared with data of patients with stroke and controls. A history of stroke or transient ischemic attacks was present in 4/30 males (13%) and 5/57 (9%) females with Fabry disease, all in the anterior circulation. Only one man with Fabry disease showed confluent cerebral white matter lesions in the Fazekas score assessment (1%). Male Fabry patients had a larger basilar artery (p<0.01) and posterior cerebral artery diameter (p<0.05) compared to male controls. This was independent of disease severity as measured by renal function and did not lead to changes in arterial blood flow properties. A basilar artery diameter of >3.2 mm distinguished between men with Fabry disease and controls (sensitivity: 87%, specificity: 86%, p<0.001), but not from stroke patients. Enlarged arterial diameters of the posterior circulation are present only in men with Fabry disease independent of disease severity.
Objective: We investigated cerebral opioid receptor binding potential in patients with fibromyalgia syndrome (FMS) using positron-emission-tomography (PET) and correlated our results with patients’ systemic interleukin-4 (IL-4) gene expression.
Methods: In this pilot study, seven FMS patients (1 man, 6 women) agreed to participate in experimental PET scans. All patients underwent neurological examination, were investigated with questionnaires for pain, depression, and FMS symptoms. Additionally, blood for IL-4 gene expression analysis was withdrawn at two time points with a median latency of 1.3 years. Patients were investigated in a PET scanner using the opioid receptor ligand F-18-fluoro-ethyl-diprenorphine ([18F]FEDPN) and results were compared with laboratory normative values.
Results: Neurological examination was normal in all FMS patients. Reduced opioid receptor binding was found in mid cingulate cortex compared to healthy controls (p < 0.005). Interestingly, three patients with high systemic IL-4 gene expression had increased opioid receptor binding in the fronto-basal cortex compared to those with low IL-4 gene expression (p < 0.005).
Conclusion: Our data give further evidence for a reduction in cortical opioid receptor availability in FMS patients as another potential central nervous system contributor to pain in FMS.
Fabry disease is an X-linked lysosomal storage disorder due to impaired activity of alpha-galactosidase A with intracellular accumulation of globotriaosylceramide. Associated small fiber pathology leads to characteristic pain in Fabry disease. We systematically assessed sensory system, physical activity, metabolic parameters, and morphology of male and female mice with alpha-galactosidase A deficiency (Fabry ko) from 2 to 27 months of age and compared results with those of age- and gender-matched wild-type littermates of C57Bl/6J background. Results From the age of two months, male and female Fabry mice showed mechanical hypersensitivity (p < 0.001 each) compared to wild-type littermates. Young Fabry ko mice of both genders were hypersensitive to heat stimulation (p < 0.01) and developed heat hyposensitivity with aging (p < 0.05), while cold hyposensitivity was present constantly in young (p < 0.01) and old (p < 0.05) Fabry ko mice compared to wild-type littermates. Stride angle increased only in male Fabry ko mice with aging (p < 0.01) in comparison to wild-type littermates. Except for young female mice, male (p < 0.05) and female (p < 0.01) Fabry ko mice had a higher body weight than wild-type littermates. Old male Fabry ko mice were physically less active than their wild-type littermates (p < 0.05), had lower chow intake (p < 0.001), and lost more weight (p < 0.001) in a one-week treadmill experiment than wild-type littermates. Also, Fabry ko mice showed spontaneous pain protective behavior and developed orofacial dysmorphism resembling patients with Fabry disease.
Conclusions. Mice with alpha-galactosidase A deficiency show age-dependent and distinct deficits of the sensory system. alpha-galactosidase A-deficient mice seem to model human Fabry disease and may be helpful when studying the pathophysiology of Fabry-associated pain.
Background: To perform a systematic review and meta-analysis on cytokine levels in patients with fibromyalgia syndrome (FMS). Methods: Through December 2010 we systematically reviewed the databases PubMed, MEDLINE, and PsycINFO and screened the reference lists of 22 review articles for suitable original articles. Original articles investigating cytokines in patients with FMS were included. Data were extracted by two independent authors. Differences of the cytokine levels of FMS patients and controls were summarized by standardized mean differences (SMD) using a random effects model. Study quality was assessed applying methodological scores: modified Center of Evidence Based Medicine, Newcastle-Ottawa-Scale, and Würzburg Methodological Quality Score. Results: Twenty-five articles were included investigating 1255 FMS patients and 800 healthy controls. Data of 13/25 studies entered meta-analysis. The overall methodological quality of studies was low. The results of the majority of studies were not comparable because methods, investigated material, and investigated target cytokines differed. Systematic review of the selected 25 articles revealed that FMS patients had higher serum levels of interleukin (IL)-1 receptor antagonist, IL-6, and IL-8, and higher plasma levels of IL-8. Meta-analysis of eligible studies showed that FMS patients had higher plasma IL-6 levels compared to controls (SMD = -0.34 [-0.64, -0.03] 95% CI; p = 0.03). The majority of investigated cytokines were not different between patients and controls. Conclusions: The pathophysiological role of cytokines in FMS is still unclear. Studies of higher quality and with higher numbers of subjects are needed.
Introduction/Aims
Schwann cell clusters have been described at the murine dermis-epidermis border. We quantified dermal Schwann cells in the skin of patients with small-fiber neuropathy (SFN) compared with healthy controls to correlate with the clinical phenotype.
Methods
Skin punch biopsies from the lower legs of 28 patients with SFN (11 men, 17 women; median age, 54 [range, 19-73] years) and 9 healthy controls (five men, four women, median age, 34 [range, 25-69] years) were immunoreacted for S100 calcium-binding protein B as a Schwann cell marker, protein-gene product 9.5 as a pan-neuronal marker, and CD207 as a Langerhans cell marker. Intraepidermal nerve fiber density (IENFD) and subepidermal Schwann cell counts were determined.
Results
Skin samples of patients with SFN showed lower IENFD (P < .05), fewer Schwann cells per millimeter (P < .01), and fewer Schwann cell clusters per millimeter (P < .05) than controls. When comparing SFN patients with reduced (n = 13; median age, 53 [range, 19-73] years) and normal distal (n = 15, median age, 54 [range, 43-68] years) IENFD, the number of solitary Schwann cells per millimeter (p < .01) and subepidermal nerve fibers associated with Schwann cell branches (P < .05) were lower in patients with reduced IENFD. All three parameters correlated positively with distal IENFD (P < .05 to P < .01), whereas no correlation was found between Schwann cell counts and clinical pain characteristics.
Discussion
Our data raise questions about the mechanisms underlying the interdependence of dermal Schwann cells and skin innervation in SFN. The temporal course and functional impact of Schwann cell presence and kinetics need further investigation.
Background:
Clinical reasoning in Neurology is based on general associations which help to deduce the site of the lesion. However, even “golden principles” may occasionally be deceptive. Here, we describe the case of subacute flaccid tetraparesis due to motor cortical lesions. To our knowledge, this is the first report to include an impressive illustration of nearly symmetric motor cortical involvement of encephalitis on brain MRI.
Case presentation:
A 51 year old immunocompromized man developed a high-grade pure motor flaccid tetraparesis over few days. Based on clinical presentation, critical illness polyneuromyopathy was suspected. However, brain MRI revealed symmetrical hyperintensities strictly limited to the subcortical precentral gyrus. An encephalitis, possibly due to CMV infection, turned out to be the most likely cause.
Conclusion:
While recognition of basic clinical patterns is indispensable in neurological reasoning, awareness of central conditions mimicking peripheral nervous disease may be crucial to detect unsuspected, potentially treatable conditions.
Background: Compensation of brain injury in multiple sclerosis (MS) may in part work through mechanisms involving neuronal plasticity on local and interregional scales. Mechanisms limiting excessive neuronal activity may have special significance for retention and (re-)acquisition of lost motor skills in brain injury. However, previous neurophysiological studies of plasticity in MS have investigated only excitability enhancing plasticity and results from neuroimaging are ambiguous. Thus, the aim of this study was to probe long-term depression-like central motor plasticity utilizing continuous theta-burst stimulation (cTBS), a non-invasive brain stimulation protocol. Because cTBS also may trigger behavioral effects through local interference with neuronal circuits, this approach also permitted investigating the functional role of the primary motor cortex (M1) in force control in patients with MS. Methods: We used cTBS and force recordings to examine long-term depression-like central motor plasticity and behavioral consequences of a M1 lesion in 14 patients with stable mild-to-moderate MS (median EDSS 1.5, range 0 to 3.5) and 14 age-matched healthy controls. cTBS consisted of bursts (50 Hz) of three subthreshold biphasic magnetic stimuli repeated at 5 Hz for 40 s over the hand area of the left M1. Corticospinal excitability was probed via motor-evoked potentials (MEP) in the abductor pollicis brevis muscle over M1 before and after cTBS. Force production performance was assessed in an isometric right thumb abduction task by recording the number of hits into a predefined force window. Results: cTBS reduced MEP amplitudes in the contralateral abductor pollicis brevis muscle to a comparable extent in control subjects (69 ± 22% of baseline amplitude, p < 0.001) and in MS patients (69 ± 18%, p < 0.001). In contrast, postcTBS force production performance was only impaired in controls (2.2 ± 2.8, p = 0.011), but not in MS patients (2.0 ± 4.4, p = 0.108). The decline in force production performance following cTBS correlated with corticomuscular latencies (CML) in MS patients, but did not correlate with MEP amplitude reduction in patients or controls. Conclusions: Long-term depression-like plasticity remains largely intact in mild-to-moderate MS. Increasing brain injury may render the neuronal networks less responsive toward lesion-induction by cTBS.
Background
Atrial fibrillation (AF) is present in 15–20% of patients with acute ischemic stroke. Oral anticoagulation reduces the risk of AF-related recurrent stroke but clinical guideline recommendations are rather vague regarding its use in the acute phase of stroke. We aimed to assess the current clinical practice of medical stroke prevention in AF patients during the acute phase of ischemic stroke.
Methods
In April 2017, a standardized anonymous questionnaire was sent to clinical leads of all 298 certified stroke units in Germany.
Results
Overall, 154 stroke unit leads participated (response rate 52%). Anticoagulation in the acute phase of stroke is considered feasible in more than 90% of AF patients with ischemic stroke. Clinicians assume that about two thirds of all AF patients (range 20–100%) are discharged on oral anticoagulation. According to local preferences, acetylsalicylic acid is given orally in the majority of patients with delayed initiation of oral anticoagulation. A non-vitamin K-dependent oral anticoagulant (NOAC) is more often prescribed than a vitamin K-dependent oral anticoagulant (VKA). VKA is more often chosen in patients with previous VKA intake than in VKA naive patients. In the minority of patients, stroke unit leads discuss the prescription of a specific oral anticoagulant with the treating general practitioner. Adherence to medical stroke prevention after hospital discharge is not assessed on a regular basis in any patient by the majority of participating stroke centers.
Conclusions
Early secondary stroke prevention in AF patients in German stroke units is based on OAC use but prescription modalities vary in clinical practice.
Background. Missed or delayed detection of progressive neuronal damage after traumatic brain injury (TBI) may have negative impact on the outcome. We investigated whether routine follow-up CT is beneficial in sedated and mechanically ventilated trauma patients. Methods. The study design is a retrospective chart review. A routine follow-up cCT was performed 6 hours after the admission scan. We defined 2 groups of patients, group I: patients with equal or recurrent pathologies and group II: patients with new findings or progression of known pathologies. Results. A progression of intracranial injury was found in 63 patients (42%) and 18 patients (12%) had new findings in cCT 2 (group II). In group II a change in therapy was found in 44 out of 81 patients (54%). 55 patients with progression or new findings on the second cCT had no clinical signs of neurological deterioration. Of those 24 patients (44%) had therapeutic consequences due to the results of the follow-up cCT. Conclusion. We found new diagnosis or progression of intracranial pathology in 54% of the patients. In 54% of patients with new findings and progression of pathology, therapy was changed due to the results of follow-up cCT. In trauma patients who are sedated and ventilated for different reasons a routine follow-up CT is beneficial.
Background
Serotonin (5-hydroxytryptamin, 5-HT) is an indolamine platelet agonist, biochemically derived from tryptophan. 5-HT is secreted from the enterochromaffin cells into the gastrointestinal tract and blood. Blood 5-HT has been proposed to regulate hemostasis by acting as a vasoconstrictor and by triggering platelet signaling through 5-HT receptor 2A (5HTR2A). Although platelets do not synthetize 5-HT, they take 5-HT up from the blood and store it in their dense granules which are secreted upon platelet activation.
Objective
To identify the molecular composite of the 5-HT uptake system in platelets and elucidate the role of platelet released 5-HT in thrombosis and ischemic stroke. Methods: 5-HT transporter knockout mice (5Htt\(^{-/-}\)) were analyzed in different in vitro and in vivo assays and in a model of ischemic stroke.
Results
In 5Htt\(^{-/-}\) platelets, 5-HT uptake from the blood was completely abolished and agonist-induced Ca2+ influx through store operated Ca\(^{2+}\) entry (SOCE), integrin activation, degranulation and aggregation responses to glycoprotein VI (GPVI) and C-type lectin-like receptor 2 (CLEC-2) were reduced. These observed in vitro defects in 5Htt\(^{-/-}\) platelets could be normalized by the addition of exogenous 5-HT. Moreover, reduced 5-HT levels in the plasma, an increased bleeding time and the formation of unstable thrombi were observed ex vivo under flow and in vivo in the abdominal aorta and carotid artery of 5Htt\(^{-/-}\) mice. Surprisingly, in the transient middle cerebral artery occlusion (tMCAO) model of ischemic stroke 5Htt\(^{-/-}\) mice showed nearly normal infarct volume and the neurological outcome was comparable to control mice.
Conclusion
Although secreted platelet 5-HT does not appear to play a crucial role in the development of reperfusion injury after stroke, it is essential to amplify the second phase of platelet activation through SOCE and plays an important role in thrombus stabilization.
Spinal muscular atrophy (SMA) is a disabling disease that affects not only the patient’s health-related quality of life (HRQoL), but also causes a high caregiver burden (CGB). The aim of this study was to evaluate HRQoL, CGB, and their predictors in SMA. In two prospective, cross-sectional, and multi-center studies, SMA patients (n = 39) and SMA patient/caregiver couples (n = 49) filled in the EuroQoL Five Dimension Five Level Scale (EQ-5D-5L) and the Short Form Health Survey 36 (SF-36). Caregivers (CGs) additionally answered the Zarit Burden Interview (ZBI) and the Hospital Anxiety and Depression Scale (HADS). Patients were clustered into two groups with either low or high HRQoL (EQ-5D-5L index value <0.259 or >0.679). The latter group was mostly composed of ambulatory type III patients with higher motor/functional scores. More severely affected patients reported low physical functioning but good mental health and vitality. The CGB (mean ZBI = 22/88) correlated negatively with patients’ motor/functional scores and age. Higher CGB was associated with a lower HRQoL, higher depression and anxiety, and more health impairments of the CGs. We conclude that patient and CG well-being levels interact closely, which highlights the need to consider the health of both parties while evaluating novel treatments.
Comprehensive investigation in motor neuron disease is vital not to miss a treatable differential diagnosis. Neuroborreliosis should be considered during an ALS work‐up. However, false‐positive CSF results do occur, and thus, results should be interpreted carefully in context of all clinical test results.
Glycine receptor β–targeting autoantibodies contribute to the pathology of autoimmune diseases
(2024)
Background and Objectives
Stiff-person syndrome (SPS) and progressive encephalomyelitis with rigidity and myoclonus (PERM) are rare neurologic disorders of the CNS. Until now, exclusive GlyRα subunit–binding autoantibodies with subsequent changes in function and surface numbers were reported. GlyR autoantibodies have also been described in patients with focal epilepsy. Autoimmune reactivity against the GlyRβ subunits has not yet been shown. Autoantibodies against GlyRα1 target the large extracellular N-terminal domain. This domain shares a high degree of sequence homology with GlyRβ making it not unlikely that GlyRβ-specific autoantibody (aAb) exist and contribute to the disease pathology.
Methods
In this study, we investigated serum samples from 58 patients for aAb specifically detecting GlyRβ. Studies in microarray format, cell-based assays, and primary spinal cord neurons and spinal cord tissue immunohistochemistry were performed to determine specific GlyRβ binding and define aAb binding to distinct protein regions. Preadsorption approaches of aAbs using living cells and the purified extracellular receptor domain were further used. Finally, functional consequences for inhibitory neurotransmission upon GlyRβ aAb binding were resolved by whole-cell patch-clamp recordings.
Results
Among 58 samples investigated, cell-based assays, tissue analysis, and preadsorption approaches revealed 2 patients with high specificity for GlyRβ aAb. Quantitative protein cluster analysis demonstrated aAb binding to synaptic GlyRβ colocalized with the scaffold protein gephyrin independent of the presence of GlyRα1. At the functional level, binding of GlyRβ aAb from both patients to its target impair glycine efficacy.
Discussion
Our study establishes GlyRβ as novel target of aAb in patients with SPS/PERM. In contrast to exclusively GlyRα1-positive sera, which alter glycine potency, aAbs against GlyRβ impair receptor efficacy for the neurotransmitter glycine. Imaging and functional analyses showed that GlyRβ aAbs antagonize inhibitory neurotransmission by affecting receptor function rather than localization.
Genetic deficiency for acid sphingomyelinase or its pharmacological inhibition has been shown to increase Foxp3\(^+\) regulatory T-cell frequencies among CD4\(^+\) T cells in mice. We now investigated whether pharmacological targeting of the acid sphingomyelinase, which catalyzes the cleavage of sphingomyelin to ceramide and phosphorylcholine, also allows to manipulate relative CD4\(^+\) Foxp3\(^+\) regulatory T-cell frequencies in humans. Pharmacological acid sphingomyelinase inhibition with antidepressants like sertraline, but not those without an inhibitory effect on acid sphingomyelinase activity like citalopram, increased the frequency of Foxp3\(^+\) regulatory T cell among human CD4\(^+\) T cells in vitro. In an observational prospective clinical study with patients suffering from major depression, we observed that acid sphingomyelinase-inhibiting antidepressants induced a stronger relative increase in the frequency of CD4\(^+\) Foxp3\(^+\) regulatory T cells in peripheral blood than acid sphingomyelinase-non- or weakly inhibiting antidepressants. This was particularly true for CD45RA\(^-\) CD25\(^{high}\) effector CD4\(^+\) Foxp3\(^+\) regulatory T cells. Mechanistically, our data indicate that the positive effect of acid sphingomyelinase inhibition on CD4\(^+\) Foxp3\(^+\) regulatory T cells required CD28 co-stimulation, suggesting that enhanced CD28 co-stimulation was the driver of the observed increase in the frequency of Foxp3+ regulatory T cells among human CD4\(^+\) T cells. In summary, the widely induced pharmacological inhibition of acid sphingomyelinase activity in patients leads to an increase in Foxp3+ regulatory T-cell frequencies among CD4\(^+\) T cells in humans both in vivo and in vitro.
Background: Severe brain edema is observed in a number of patients suffering from subarachnoid hemorrhage (SAH). Little is known about its pathogenesis and time-course in the first hours after SAH. This study was performed to investigate the development of brain edema and its correlation with brain perfusion after experimental SAH. Methods: Male Sprague–Dawley rats, randomly assigned to one of six groups (n = 8), were subjected to SAH using the endovascular filament model or underwent a sham operation. Animals were sacrificed 15, 30, 60, 180 or 360 minutes after SAH. Intracranial pressure (ICP), mean arterial blood pressure (MABP), cerebral perfusion pressure (CPP) and bilateral local cerebral blood flow (LCBF) were continuously measured. Brain water content (BWC) was determined by the wet/dry-weight method. Results: After SAH, CPP and LCBF rapidly decreased. The decline of LCBF markedly exceeded the decline of CPP and persisted until the end of the observation period. BWC continuously increased. A significant correlation was observed between the BWC and the extent of the perfusion deficit in animals sacrificed after 180 and 360 minutes. Conclusions: The significant correlation with the perfusion deficit after SAH suggests that the development of brain edema is related to the extent of ischemia and acute vasoconstriction in the first hours after SAH.
Background
Mobile 3D fluoroscopes have become increasingly available in neurosurgical operating rooms. In this series, the image quality and value of intraoperative 3D fluoroscopy with intravenous contrast agent for the evaluation of aneurysm occlusion and vessel patency after clip placement was assessed in patients who underwent surgery for intracranial aneurysms.
Materials and methods
Twelve patients were included in this retrospective analysis. Prior to surgery, a 360° rotational fluoroscopy scan was performed without contrast agent followed by another scan with 50 ml of intravenous iodine contrast agent. The image files of both scans were transferred to an Apple PowerMac® workstation, subtracted and reconstructed using OsiriX® free software. The procedure was repeated after clip placement. Both image sets were compared for assessment of aneurysm occlusion and vessel patency.
Results
Image acquisition and contrast administration caused no adverse effects. Image quality was sufficient to follow the patency of the vessels distal to the clip. Metal artifacts reduce the assessability of the immediate vicinity of the clip. Precise image subtraction and post-processing can reduce metal artifacts and make the clip-site assessable and depict larger neck-remnants.
Conclusion
This technique quickly supplies images at adequate quality to evaluate distal vessel patency after aneurysm clipping. Significant aneurysm remnants may be depicted as well. As it does not require visual control of all vessels that are supposed to be evaluated intraoperatively, this technique may be complementary to other intraoperative tools like indocyanine green videoangiography and micro-Doppler, especially for the assessment of larger aneurysms. At the momentary state of this technology, it cannot replace postoperative conventional angiography. However, 3D fluoroscopy and image post-processing are young technologies. Further technical developments are likely to result in improved image quality.
Background. Intraoperative myelography has been reported for decompression control in multilevel lumbar disease. Cervical myelography is technically more challenging. Modern 3D fluoroscopy may provide a new opportunity supplying multiplanar images. This study was performed to determine the feasibility and image quality of intraoperative cervical myelography using a 3D fluoroscope. Methods. The series included 9 patients with multilevel cervical stenosis. After decompression, 10 mL of water-soluble contrast agent was administered via a lumbar drainage and the operating table was tilted. Thereafter, a 3D fluoroscopy scan (O-Arm) was performed and visually evaluated. Findings. The quality of multiplanar images was sufficient to supply information about the presence of residual stenosis. After instrumentation, metal artifacts lowered image quality. In 3 cases, decompression was continued because myelography depicted residual stenosis. In one case, anterior corpectomy was not completed because myelography showed sufficient decompression after 2-level discectomy. Interpretation. Intraoperative myelography using 3D rotational fluoroscopy is useful for the control of surgical decompression in multilevel spinal stenosis providing images comparable to postmyelographic CT. The long duration of contrast delivery into the cervical spine may be solved by preoperative contrast administration. The method is susceptible to metal artifacts and, therefore, should be applied before metal implants are placed.
Unlike other organs the nervous system is secluded from the rest of the organism by the blood brain barrier (BBB) or blood nerve barrier (BNB) preventing passive influx of fluids from the circulation. Similarly, leukocyte entry to the nervous system is tightly controlled. Breakdown of these barriers and cellular inflammation are hallmarks of inflammatory as well as ischemic neurological diseases and thus represent potential therapeutic targets. The spatiotemporal relationship between BBB/BNB disruption and leukocyte infiltration has been a matter of debate. We here review contrast-enhanced magnetic resonance imaging (MRI) as a non-invasive tool to depict barrier dysfunction and its relation to macrophage infiltration in the central and peripheral nervous system under pathological conditions. Novel experimental contrast agents like Gadofluorine M (Gf) allow more sensitive assessment of BBB dysfunction than conventional Gadolinium (Gd)-DTPA enhanced MRI. In addition, Gf facilitates visualization of functional and transient alterations of the BBB remote from lesions. Cellular contrast agents such as superparamagnetic iron oxide particles (SPIO) and perfluorocarbons enable assessment of leukocyte (mainly macrophage) infiltration by MR technology. Combined use of these MR contrast agents disclosed that leukocytes can enter the nervous system independent from a disturbance of the BBB, and vice versa, a dysfunctional BBB/BNB by itself is not sufficient to attract inflammatory cells from the circulation. We will illustrate these basic imaging findings in animal models of multiple sclerosis, cerebral ischemia, and traumatic nerve injury and review corresponding findings in patients.
In Vivo Imaging of Stepwise Vessel Occlusion in Cerebral Photothrombosis of Mice by \(^{19}\)F MRI
(2011)
Background
\(^{19}\)F magnetic resonance imaging (MRI) was recently introduced as a promising technique for in vivo cell tracking. In the present study we compared \(^{19}\)F MRI with iron-enhanced MRI in mice with photothrombosis (PT) at 7 Tesla. PT represents a model of focal cerebral ischemia exhibiting acute vessel occlusion and delayed neuroinflammation.
Methods/Principal Findings
Perfluorocarbons (PFC) or superparamagnetic iron oxide particles (SPIO) were injected intravenously at different time points after photothrombotic infarction. While administration of PFC directly after PT induction led to a strong \(^{19}\)F signal throughout the entire lesion, two hours delayed application resulted in a rim-like \(^{19}\)F signal at the outer edge of the lesion. These findings closely resembled the distribution of signal loss on T2-weighted MRI seen after SPIO injection reflecting intravascular accumulation of iron particles trapped in vessel thrombi as confirmed histologically. By sequential administration of two chemically shifted PFC compounds 0 and 2 hours after illumination the different spatial distribution of the \(^{19}\)F markers (infarct core/rim) could be visualized in the same animal. When PFC were applied at day 6 the fluorine marker was only detected after long acquisition times ex vivo. SPIO-enhanced MRI showed slight signal loss in vivo which was much more prominent ex vivo indicative for neuroinflammation at this late lesion stage.
Conclusion
Our study shows that vessel occlusion can be followed in vivo by \(^{19}\)F and SPIO-enhanced high-field MRI while in vivo imaging of neuroinflammation remains challenging. The timing of contrast agent application was the major determinant of the underlying processes depicted by both imaging techniques. Importantly, sequential application of different PFC compounds allowed depiction of ongoing vessel occlusion from the core to the margin of the ischemic lesions in a single MRI measurement.
α-Synuclein is a protein implicated in the etiopathogenesis of Parkinson’s disease (PD). AAV1/2-driven overexpression of human mutated A53T-α-synuclein in rat and monkey substantia nigra (SN) induces degeneration of nigral dopaminergic neurons and decreases striatal dopamine and tyrosine hydroxylase (TH). Given certain advantages of the mouse, especially it being amendable to genetic manipulation, translating the AAV1/2-A53T α-synuclein model to mice would be of significant value. AAV1/2-A53T α-synuclein or AAV1/2 empty vector (EV) at a concentration of 5.16 x 10\(^{12}\) gp/ml were unilaterally injected into the right SN of male adult C57BL/6 mice. Post-mortem examinations included immunohistochemistry to analyze nigral α-synuclein, Ser129 phosphorylated α-synuclein and TH expression, striatal dopamine transporter (DAT) levels by autoradiography and dopamine levels by high performance liquid chromatography. At 10 weeks, in AAV1/2-A53T α-synuclein mice there was a 33% reduction in TH+ dopaminergic nigral neurons (P < 0.001), 29% deficit in striatal DAT binding (P < 0.05), 38% and 33% reductions in dopamine (P < 0.001) and DOPAC (P < 0.01) levels and a 60% increase in dopamine turnover (homovanilic acid/dopamine ratio; P < 0.001). Immunofluorescence showed that the AAV1/2-A53T α-synuclein injected mice had widespread nigral and striatal expression of vector-delivered A53T-α-synuclein. Concurrent staining with human PD SN samples using gold standard histological methodology for Lewy pathology detection by proteinase K digestion and application of specific antibody raised against human Lewy body α-synuclein (LB509) and Ser129 phosphorylated α-synuclein (81A) revealed insoluble α-synuclein aggregates in AAV1/2-A53T α-synuclein mice resembling Lewy-like neurites and bodies. In the cylinder test, we observed significant paw use asymmetry in the AAV1/2-A53T α-synuclein group when compared to EV controls at 5 and 9 weeks post injection (P < 0.001; P < 0.05). These data show that unilateral injection of AAV1/2-A53T α-synuclein into the mouse SN leads to persistent motor deficits, neurodegeneration of the nigrostriatal dopaminergic system and development of Lewy-like pathology, thereby reflecting clinical and pathological hallmarks of human PD.
Treatment of dysferlinopathy with deflazacort: a double-blind, placebo-controlled clinical trial
(2013)
Background: Dysferlinopathies are autosomal recessive disorders caused by mutations in the dysferlin (DYSF) gene encoding the dysferlin protein. DYSF mutations lead to a wide range of muscular phenotypes, with the most prominent being Miyoshi myopathy (MM) and limb girdle muscular dystrophy type 2B (LGMD2B).
Methods: We assessed the one-year-natural course of dysferlinopathy, and the safety and efficacy of deflazacort treatment in a double-blind, placebo-controlled cross-over trial. After one year of natural course without intervention, 25 patients with genetically defined dysferlinopathy were randomized to receive deflazacort and placebo for six months each (1 mg/kg/day in month one, 1 mg/kg every 2nd day during months two to six) in one of two treatment sequences. Results: During one year of natural course, muscle strength declined about 2% as measured by CIDD (Clinical Investigation of Duchenne Dystrophy) score, and 76 Newton as measured by hand-held dynamometry. Deflazacort did not improve muscle strength. In contrast, there is a trend of worsening muscle strength under deflazacort treatment, which recovers after discontinuation of the study drug. During deflazacort treatment, patients showed a broad spectrum of steroid side effects.
Conclusion: Deflazacort is not an effective therapy for dysferlinopathies, and off-label use is not warranted. This is an important finding, since steroid treatment should not be administered in patients with dysferlinopathy, who may be often misdiagnosed as polymyositis.
Background
Although Fabry disease (FD) is an X-linked lysosomal storage disorder caused by mutations in the α-galactosidase A gene (GLA), women may develop severe symptoms. We investigated X-chromosomal inactivation patterns (XCI) as a potential determinant of symptom severity in FD women.
Patients and Methods
We included 95 women with mutations in GLA (n = 18 with variants of unknown pathogenicity) and 50 related men, and collected mouth epithelial cells, venous blood, and skin fibroblasts for XCI analysis using the methylation status of the androgen receptor gene. The mutated X-chromosome was identified by comparison of samples from relatives. Patients underwent genotype categorization and deep clinical phenotyping of symptom severity.
Results
43/95 (45%) women carried mutations categorized as classic. The XCI pattern was skewed (i.e., ≥75:25% distribution) in 6/87 (7%) mouth epithelial cell samples, 31/88 (35%) blood samples, and 9/27 (33%) skin fibroblast samples. Clinical phenotype, α-galactosidase A (GAL) activity, and lyso-Gb3 levels did not show intergroup differences when stratified for X-chromosomal skewing and activity status of the mutated X-chromosome.
Conclusions
X-inactivation patterns alone do not reliably reflect the clinical phenotype of women with FD when investigated in biomaterial not directly affected by FD. However, while XCI patterns may vary between tissues, blood frequently shows skewing of XCI patterns.
Motor complications in Parkinson’s disease (PD) result from the short half-life and irregular plasma fluctuations of oral levodopa. When strategies of providing more continuous dopaminergic stimulation by adjusting oral medication fail, patients may be candidates for one of three device-aided therapies: deep brain stimulation (DBS), continuous subcutaneous apomorphine infusion, or continuous duodenal/jejunal levodopa/carbidopa pump infusion (DLI). These therapies differ in their invasiveness, side-effect profile, and the need for nursing care. So far, very few comparative studies have evaluated the efficacy of the three device-aided therapies for specific motor problems in advanced PD. As a result, neurologists currently lack guidance as to which therapy could be most appropriate for a particular PD patient. A group of experts knowledgeable in all three therapies reviewed the currently available literature for each treatment and identified variables of clinical relevance for choosing one of the three options such as type of motor problems, age, and cognitive and psychiatric status. For each scenario, pragmatic and (if available) evidence-based recommendations are provided as to which patients could be candidates for either DBS, DLI, or subcutaneous apomorphine.
Background
It is unknown whether technological advancement of stent-retriever devices influences typical observational indicators of safety or effectiveness.
Methods
Observational retrospective study of APERIO® (AP) vs. new generation APERIO® Hybrid (APH) (Acandis®, Pforzheim, Germany) stent-retriever device (01/2019–09/2020) for mechanical thrombectomy (MT) in large vessel occlusion (LVO) stroke. Primary effectiveness endpoint was successful recanalization eTICI (expanded Thrombolysis In Cerebral Ischemia) ≥ 2b67, primary safety endpoint was occurrence of hemorrhagic complications after MT. Secondary outcome measures were time from groin puncture to first pass and successful reperfusion, and the total number of passes needed to achieve the final recanalization result.
Results
A total of 298 patients with LVO stroke who were treated by MT matched the inclusion criteria: 148 patients (49.7%) treated with AP vs. 150 patients (50.3%) treated with new generation APH. Successful recanalization was not statistically different between both groups: 75.7% for AP vs. 79.3% for APH; p = 0.450. Postinterventional hemorrhagic complications and particularly subarachnoid hemorrhage as the entity possibly associated with stent-retriever device type was significantly less frequent in the group treated with the APH: 29.7% for AP and 16.0% for APH; p = 0.005; however, rates of symptomatic hemorrhage with clinical deterioration and in domo mortality were not statistically different. Neither the median number of stent-retriever passages needed to achieve final recanalization, time from groin puncture to first pass, time from groin puncture to final recanalization nor the number of cases in which successful recanalization could only be achieved by using a different stent-retriever as bail-out device differed between both groups.
Conclusion
In the specific example of the APERIO® stent-retriever device, we observed that further technological developments of the new generation device were not associated with disadvantages with respect to typical observational indicators of safety or effectiveness.
The calpain inhibitor MDL-28710 blocks the early local pro-inflammatory cytokine gene expression in mice after chronic constriction nerve injury (CCI). Onehundred- thirteen wild type mice of C57Bl/6J background received CCI of the right sciatic nerve. Mechanical paw withdrawal thresholds and thermal withdrawal latencies were investigated at baseline and at 1, 3, and 7 days after CCI. Three application regimens were used for MDL-28170: a) single injection 40 min before CCI; b) serial injections of MDL- 28170 40 min before and up to day three after CCI; c) sustained application via intraperitoneal osmotic pumps. The control animals received the vehicle DMSO/PEG 400. The tolerable dose of MDL-28170 for mice was 30 mg/kg body weight, higher doses were lethal within the first hours after application. Mechanical withdrawal thresholds and thermal withdrawal latencies were reduced after CCI and did not normalize after single or serial injections, nor with application of MDL-28170 via osmotic pumps. Although the calpain inhibitor MDL-28170 inhibits the early local cytokine upregulation in the sciatic nerve after CCI, pain behavior is not altered. This finding implies that local cytokine upregulation after nerve injury alone is only one factor in the induction and maintenance of neuropathic pain.
Aims
We aimed to analyze prevalence and predictors of NOAC off-label under-dosing in AF patients before and after the index stroke.
Methods
The post hoc analysis included 1080 patients of the investigator-initiated, multicenter prospective Berlin Atrial Fibrillation Registry, designed to analyze medical stroke prevention in AF patients after acute ischemic stroke.
Results
At stroke onset, an off-label daily dose was prescribed in 61 (25.5%) of 239 NOAC patients with known AF and CHA2DS2-VASc score ≥ 1, of which 52 (21.8%) patients were under-dosed. Under-dosing was associated with age ≥ 80 years in patients on rivaroxaban [OR 2.90, 95% CI 1.05-7.9, P = 0.04; n = 29] or apixaban [OR 3.24, 95% CI 1.04-10.1, P = 0.04; n = 22]. At hospital discharge after the index stroke, NOAC off-label dose on admission was continued in 30 (49.2%) of 61 patients. Overall, 79 (13.7%) of 708 patients prescribed a NOAC at hospital discharge received an off-label dose, of whom 75 (10.6%) patients were under-dosed. Rivaroxaban under-dosing at discharge was associated with age ≥ 80 years [OR 3.49, 95% CI 1.24-9.84, P = 0.02; n = 19]; apixaban under-dosing with body weight ≤ 60 kg [OR 0.06, 95% CI 0.01-0.47, P < 0.01; n = 56], CHA2DS2-VASc score [OR per point 1.47, 95% CI 1.08-2.00, P = 0.01], and HAS-BLED score [OR per point 1.91, 95% CI 1.28-2.84, P < 0.01].
Conclusion
At stroke onset, off-label dosing was present in one out of four, and under-dosing in one out of five NOAC patients. Under-dosing of rivaroxaban or apixaban was related to old age. In-hospital treatment after stroke reduced off-label NOAC dosing, but one out of ten NOAC patients was under-dosed at discharge.
Aims
Cognitive dysfunction occurs frequently in patients with heart failure (HF), but early detection remains challenging. Serum glial fibrillary acidic protein (GFAP) is an emerging biomarker of cognitive decline in disorders of primary neurodegeneration such as Alzheimer's disease. We evaluated the utility of serum GFAP as a biomarker for cognitive dysfunction and structural brain damage in patients with stable chronic HF.
Methods and results
Using bead-based single molecule immunoassays, we quantified serum levels of GFAP in patients with HF participating in the prospective Cognition.Matters-HF study. Participants were extensively phenotyped, including cognitive testing of five separate domains and magnetic resonance imaging (MRI) of the brain. Univariable and multivariable models, also accounting for multiple testing, were run. One hundred and forty-six chronic HF patients with a mean age of 63.8 ± 10.8 years were included (15.1% women). Serum GFAP levels (median 246 pg/mL, quartiles 165, 384 pg/mL; range 66 to 1512 pg/mL) did not differ between sexes. In the multivariable adjusted model, independent predictors of GFAP levels were age (T = 5.5; P < 0.001), smoking (T = 3.2; P = 0.002), estimated glomerular filtration rate (T = −4.7; P < 0.001), alanine aminotransferase (T = −2.1; P = 0.036), and the left atrial end-systolic volume index (T = 3.4; P = 0.004). NT-proBNP but not serum GFAP explained global cerebral atrophy beyond ageing. However, serum GFAP levels were associated with the cognitive domain visual/verbal memory (T = −3.0; P = 0.003) along with focal hippocampal atrophy (T = 2.3; P = 0.025).
Conclusions
Serum GFAP levels are affected by age, smoking, and surrogates of the severity of HF. The association of GFAP with memory dysfunction suggests that astroglial pathologies, which evade detection by conventional MRI, may contribute to memory loss beyond ageing in patients with chronic HF.
Background
Chronic heart failure (HF) is known to increase the risk of developing Alzheimer’s dementia significantly. Thus, detecting and preventing mild cognitive impairment, which is common in patients with HF, is of great importance. Serum biomarkers are increasingly used in neurological disorders for diagnostics, monitoring, and prognostication of disease course. It remains unclear if neuronal biomarkers may help detect cognitive impairment in this high-risk population. Also, the influence of chronic HF and concomitant renal dysfunction on these biomarkers is not well understood.
Methods
Within the monocentric Cognition.Matters-HF study, we quantified the serum levels of phosphorylated tau protein 181 (pTau) and neurofilament light chain (NfL) of 146 extensively phenotyped chronic heart failure patients (aged 32 to 85 years; 15.1% women) using ultrasensitive bead-based single-molecule immunoassays. The clinical work-up included advanced cognitive testing and cerebral magnetic resonance imaging (MRI).
Results
Serum concentrations of NfL ranged from 5.4 to 215.0 pg/ml (median 26.4 pg/ml) and of pTau from 0.51 to 9.22 pg/ml (median 1.57 pg/ml). We detected mild cognitive impairment (i.e., T-score < 40 in at least one cognitive domain) in 60% of heart failure patients. pTau (p = 0.014), but not NfL, was elevated in this group. Both NfL (ρ = − 0.21; p = 0.013) and pTau (ρ = − 0.25; p = 0.002) related to the cognitive domain visual/verbal memory, as well as white matter hyperintensity volume and cerebral and hippocampal atrophy. In multivariable analysis, both biomarkers were independently influenced by age (T = 4.6 for pTau; T = 5.9 for NfL) and glomerular filtration rate (T = − 2.4 for pTau; T = − 3.4 for NfL). Markers of chronic heart failure, left atrial volume index (T = 4.6) and NT-proBNP (T = 2.8), were further cardiological determinants of pTau and NfL, respectively. In addition, pTau was also strongly affected by serum creatine kinase levels (T = 6.5) and ferritin (T = − 3.1).
Conclusions
pTau and NfL serum levels are strongly influenced by age-dependent renal and cardiac dysfunction. These findings point towards the need for longitudinal examinations and consideration of frequent comorbidities when using neuronal serum biomarkers.
Acute ischemic cardiac injury predisposes one to cognitive impairment, dementia, and depression. Pathophysiologically, recent positron emission tomography data suggest astroglial activation after experimental myocardial infarction (MI). We analyzed peripheral surrogate markers of glial (and neuronal) damage serially within 12 months after the first ST-elevation MI (STEMI). Serum levels of glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) were quantified using ultra-sensitive molecular immunoassays. Sufficient biomaterial was available from 45 STEMI patients (aged 28 to 78 years, median 56 years, 11% female). The median (quartiles) of GFAP was 63.8 (47.0, 89.9) pg/mL and of NfL 10.6 (7.2, 14.8) pg/mL at study entry 0–4 days after STEMI. GFAP after STEMI increased in the first 3 months, with a median change of +7.8 (0.4, 19.4) pg/mL (p = 0.007). It remained elevated without further relevant increases after 6 months (+11.7 (0.6, 23.5) pg/mL; p = 0.015), and 12 months (+10.3 (1.5, 22.7) pg/mL; p = 0.010) compared to the baseline. Larger relative infarction size was associated with a higher increase in GFAP (ρ = 0.41; p = 0.009). In contrast, NfL remained unaltered in the course of one year. Our findings support the idea of central nervous system involvement after MI, with GFAP as a potential peripheral biomarker of chronic glial damage as one pathophysiologic pathway.
Introduction:
Evidence from a number of open-label, uncontrolled studies has suggested that rituximab may benefit patients with autoimmune diseases who are refractory to standard-of-care. The objective of this study was to evaluate the safety and clinical outcomes of rituximab in several standard-of-care-refractory autoimmune diseases (within rheumatology, nephrology, dermatology and neurology) other than rheumatoid arthritis or non-Hodgkin’s lymphoma in a real-life clinical setting.
Methods:
Patients who received rituximab having shown an inadequate response to standard-of-care had their safety and clinical outcomes data retrospectively analysed as part of the German Registry of Autoimmune Diseases. The main outcome measures were safety and clinical response, as judged at the discretion of the investigators.
Results:
A total of 370 patients (299 patient-years) with various autoimmune diseases (23.0% with systemic lupus erythematosus, 15.7% antineutrophil cytoplasmic antibody-associated granulomatous vasculitides, 15.1% multiple sclerosis and 10.0% pemphigus) from 42 centres received a mean dose of 2,440 mg of rituximab over a median (range) of 194 (180 to 1,407) days. The overall rate of serious infections was 5.3 per 100 patient-years during rituximab therapy. Opportunistic infections were infrequent across the whole study population, and mostly occurred in patients with systemic lupus erythematosus. There were 11 deaths (3.0% of patients) after rituximab treatment (mean 11.6 months after first infusion, range 0.8 to 31.3 months), with most of the deaths caused by infections. Overall (n = 293), 13.3% of patients showed no response, 45.1% showed a partial response and 41.6% showed a complete response. Responses were also reflected by reduced use of glucocorticoids and various immunosuppressives during rituximab therapy and follow-up compared with before rituximab. Rituximab generally had a positive effect on patient well-being (physician’s visual analogue scale; mean improvement from baseline of 12.1 mm)
It remains unclear if principal components of the local cerebral stroke immune response can be reliably and reproducibly observed in patients with acute large-vessel-occlusion (LVO) stroke. We prospectively studied a large independent cohort of n = 318 consecutive LVO stroke patients undergoing mechanical thrombectomy during which cerebral blood samples from within the occluded anterior circulation and systemic control samples from the ipsilateral cervical internal carotid artery were obtained. An extensive protocol was applied to homogenize the patient cohort and to standardize the procedural steps of endovascular sample collection, sample processing, and laboratory analyses. N = 58 patients met all inclusion criteria. (1) Mean total leukocyte counts were significantly higher within the occluded ischemic cerebral vasculature (I) vs. intraindividual systemic controls (S): +9.6%, I: 8114/µL ± 529 vs. S: 7406/µL ± 468, p = 0.0125. (2) This increase was driven by neutrophils: +12.1%, I: 7197/µL ± 510 vs. S: 6420/µL ± 438, p = 0.0022. Leukocyte influx was associated with (3) reduced retrograde collateral flow (R\(^2\) = 0.09696, p = 0.0373) and (4) greater infarct extent (R\(^2\) = 0.08382, p = 0.032). Despite LVO, leukocytes invade the occluded territory via retrograde collateral pathways early during ischemia, likely compromising cerebral hemodynamics and tissue integrity. This inflammatory response can be reliably observed in human stroke by harvesting immune cells from the occluded cerebral vascular compartment.
Based on recent findings that show that depletion of factor XII (FXII) leads to better posttraumatic neurological recovery, we studied the effect of FXII-deficiency on post-traumatic cognitive and behavioral outcomes in female and male mice. In agreement with our previous findings, neurological deficits on day 7 after weight-drop traumatic brain injury (TBI) were significantly reduced in FXII\(^{−/−}\) mice compared to wild type (WT) mice. Also, glycoprotein Ib (GPIb)-positive platelet aggregates were more frequent in brain microvasculature of WT than FXII\(^{−/−}\) mice 3 months after TBI. Six weeks after TBI, memory for novel object was significantly reduced in both female and male WT but not in FXII\(^{−/−}\) mice compared to sham-operated mice. In the setting of automated home-cage monitoring of socially housed mice in IntelliCages, female WT mice but not FXII\(^{−/−}\) mice showed decreased exploration and reacted negatively to reward extinction one month after TBI. Since neuroendocrine stress after TBI might contribute to trauma-induced cognitive dysfunction and negative emotional contrast reactions, we measured peripheral corticosterone levels and the ration of heart, lung, and spleen weight to bodyweight. Three months after TBI, plasma corticosterone levels were significantly suppressed in both female and male WT but not in FXII\(^{−/−}\) mice, while the relative heart weight increased in males but not in females of both phenotypes when compared to sham-operated mice. Our results indicate that FXII deficiency is associated with efficient post-traumatic behavioral and neuroendocrine recovery.
Objective
To identify and characterize patients with autoantibodies against different neurofascin (NF) isoforms.
Methods
Screening of a large cohort of patient sera for anti-NF autoantibodies by ELISA and further characterization by cell-based assays, epitope mapping, and complement binding assays.
Results
Two different clinical phenotypes became apparent in this study: The well-known clinical picture of subacute-onset severe sensorimotor neuropathy with tremor that is known to be associated with IgG4 autoantibodies against the paranodal isoform NF-155 was found in 2 patients. The second phenotype with a dramatic course of disease with tetraplegia and almost locked-in syndrome was associated with IgG3 autoantibodies against nodal and paranodal isoforms of NF in 3 patients. The epitope against which these autoantibodies were directed in this second phenotype was the common Ig domain found in all 3 NF isoforms. In contrast, anti–NF-155 IgG4 were directed against the NF-155–specific Fn3Fn4 domain. The description of a second phenotype of anti–NF-associated neuropathy is in line with some case reports of similar patients that were published in the last year.
Conclusions
Our results indicate that anti–pan-NF-associated neuropathy differs from anti–NF-155-associated neuropathy, and epitope and subclass play a major role in the pathogenesis and severity of anti–NF-associated neuropathy and should be determined to correctly classify patients, also in respect to possible differences in therapeutic response.
DYT-TOR1A is the most common inherited dystonia caused by a three nucleotide (GAG) deletion (dE) in the TOR1A gene. Death early after birth and cortical anomalies of the full knockout in rodents underscore its developmental importance. We therefore explored the timed effects of TOR1A-wt and TOR1A-dE during differentiation in a human neural in vitro model. We used lentiviral tet-ON expression of TOR1A-wt and -dE in induced neural stem cells derived from healthy donors. Overexpression was induced during proliferation of neural precursors, during differentiation and after differentiation into mature neurons. Overexpression of both wildtype and mutated protein had no effect on the viability and cell number of neural precursors as well as mature neurons when initiated before or after differentiation. However, if induced during differentiation, overexpression of TOR1A-wt and -dE led to a pronounced reduction of mature neurons in a dose dependent manner. Our data underscores the importance of physiological expression levels of TOR1A as crucial for proper neuronal differentiation. We did not find evidence for a specific impact of the mutated TOR1A on neuronal maturation.
Background
Progressive multifocal leukoencephalopathy is a demyelinating CNS disorder. Reactivation of John Cunningham virus leads to oligodendrocyte infection with lysis and consequent axonal loss due to demyelination. Patients usually present with confusion and seizures. Late diagnosis and lack of adequate therapy options persistently result in permanent impairment of brain functions. Due to profound T cell depletion, impairment of T-cell function and potent immunosuppressive factors, allogeneic hematopoietic cell transplantation recipients are at high risk for JCV reactivation. To date, PML is almost universally fatal when occurring after allo-HCT.
Methods
To optimize therapy specificity, we enriched JCV specific T-cells out of the donor T-cell repertoire from the HLA-identical, anti-JCV-antibody positive family stem cell donor by unstimulated peripheral apheresis [1]. For this, we selected T cells responsive to five JCV peptide libraries via the Cytokine Capture System technology. It enables the enrichment of JCV specific T cells via identification of stimulus-induced interferon gamma secretion.
Results
Despite low frequencies of responsive T cells, we succeeded in generating a product containing 20 000 JCV reactive T cells ready for patient infusion. The adoptive cell transfer was performed without complication. Consequently, the clinical course stabilized and the patient slowly went into remission of PML with JCV negative CSF and containment of PML lesion expansion.
Conclusion
We report for the first time feasibility of generating T cells with possible anti-JCV activity from a seropositive family donor, a variation of virus specific T-cell therapies suitable for the post allo transplant setting. We also present the unusual case for successful treatment of PML after allo-HCT via virus specific T-cell therapy.
Introduction
A novel neurostimulation system allows steering current in horizontal directions by combining segmented leads and multiple independent current control. The aim of this study was to evaluate directional DBS effects on parkinsonian motor features and adverse effects of subthalamic neurostimulation.
Methods
Seven PD patients implanted with the novel directional DBS system for bilateral subthalamic DBS underwent an extended monopolar review session during the first postoperative week, in which current thresholds were determined for rigidity control and stimulation-induced adverse effects using either directional or ring-mode settings.
Results
Effect or adverse effect thresholds were modified by directional settings for each of the 14 STN leads. Magnitude of change varied markedly between leads, as did orientation of optimal horizontal current steering.
Conclusion
Directional current steering through chronically implanted segmented electrodes is feasible, alters adverse effect and efficacy thresholds in a highly individual manner, and expands the therapeutic window in a monopolar review as compared to ring-mode DBS.
Fabry disease (FD) is a rare life-threatening disorder caused by deficiency of the alpha-galactosidase A (GLA) enzyme with a characteristic pain phenotype. Impaired GLA production or function leads to the accumulation of the cell membrane compound globotriaosylceramide (Gb3) in the neurons of the dorsal root ganglia (DRG) of FD patients. Applying immunohistochemistry (IHC) and quantitative real-time polymerase chain reaction (qRT PCR) analysis on DRG tissue of the GLA knockout (KO) mouse model of FD, we address the question of how Gb3 accumulation may contribute to FD pain and focus on the immune system and pain-associated ion channel gene expression. We show a higher Gb3 load in the DRG of young (<6 months) (p < 0.01) and old (≥12 months) (p < 0.001) GLA KO mice compared to old wildtype (WT) littermates, and an overall suppressed immune response in the DRG of old GLA KO mice, represented by a reduced number of CD206\(^+\) macrophages (p < 0.01) and lower gene expression levels of the inflammation-associated targets interleukin(IL)1b (p < 0.05), IL10 (p < 0.001), glial fibrillary acidic protein (GFAP) (p < 0.05), and leucine rich alpha-2-glycoprotein 1 (LRG1) (p < 0.01) in the DRG of old GLA KO mice compared to old WT. Dysregulation of immune-related genes may be linked to lower gene expression levels of the pain-associated ion channels calcium-activated potassium channel 3.1 (KCa3.1) and transient receptor potential ankyrin 1 channel (TRPA1). Ion channel expression might further be disturbed by impaired sphingolipid recruitment mediated via the lipid raft marker flotillin-1 (FLOT1). This impairment is represented by an increased number of FLOT1\(^+\) DRG neurons with a membranous expression pattern in old GLA KO mice compared to young GLA KO, young WT, and old WT mice (p < 0.001 each). Further, we provide evidence for aberrant behavior of GLA KO mice, which might be linked to dysregulated ion channel gene expression levels and disturbed FLOT1 distribution patterns. Behavioral testing revealed mechanical hypersensitivity in young (p < 0.01) and old (p < 0.001) GLA KO mice compared to WT, heat hypersensitivity in young GLA KO mice (p < 0.001) compared to WT, age-dependent heat hyposensitivity in old GLA KO mice (p < 0.001) compared to young GLA KO mice, and cold hyposensitivity in young (p < 0.001) and old (p < 0.001) GLA KO mice compared to WT, which well reflects the clinical phenotype observed in FD patients.
Background: Neuropathic pain must be correctly diagnosed for optimal treatment. The questionnaire named Neuropathic Pain Symptom Inventory (NPSI) was developed in its original French version to evaluate the different symptoms of neuropathic pain. We hypothesized that the NPSI might also be used to differentiate neuropathic from non-neuropathic pain. Methods: We translated the NPSI into German using a standard forward-backward translation and administered it in a case-control design to patients with neuropathic (n = 68) and non-neuropathic pain (headache and osteoarthritis, n = 169) to validate it and to analyze its discriminant properties, its sensitivity to change, and to detect neuropathic pain subgroups with distinct profiles. Results: Using a sum score (the NPSI-G score), we found sensitivity to change (r between 0.37 and 0.5 for pain items of the graded chronic pain scale) and could distinguish between neuropathic and other pain on a group basis, but not for individual patients. Post hoc development of a discriminant score with optimized diagnostic properties to distinguish neuropathic pain from non-neuropathic pain resulted in an instrument with high sensitivity (91%) and acceptable specificity (70%). We detected six different pain profiles in the patient group with neuropathic pain; three profiles were found to be distinct. Conclusions: The NPSI-G potentially combines the properties of a diagnostic tool and an instrument to identify subtypes of neuropathic pain.
Background and Objective
This updated systematic review evaluated the efficacy, tolerability and safety of opioids compared to placebo in chronic non‐cancer neuropathic pain.
Databases and Data Treatment
Clinicaltrials.gov, CENTRAL, PubMed and PsycINFO were searched from October 2013 to June 2019. Randomized controlled trials comparing opioids with placebo and at least 4 weeks double‐blinded duration were analysed. Primary outcomes were pain relief of 50% or greater, disability, tolerability and safety. Effects were summarized by a random effects model using risk differences (RD) or standardized mean differences (SMD). We added four new studies with 662 participants for a total of 16 included studies with 2,199 participants. Study duration ranged between 4 and 12 weeks. Studies with a parallel and cross‐over design: Based on low to moderate quality evidence, opioids (buprenorphine, hydromorphone, morphine, oxycodone, tramadol) provided a clinically relevant pain relief of 50% or greater and reduction of disability compared to placebo. There was no clinically relevant harm with regards to the drop out rate due to adverse and serious adverse events by opioids compared to placebo. Enriched enrolment randomized withdrawal design: Based on low to moderate quality evidence, tapentadol provided a clinically relevant pain relief of 50% or greater and reduction of disability compared to placebo in diabetic polyneuropathy. There was no clinically relevant harm with regards to the drop out rate due to adverse and serious adverse events by tapentadol compared to placebo.
Conclusions
Some opioids provided a short‐term substantial pain relief in highly selected patients in some neuropathic pain syndromes.
Significance
Some opioids (buprenorphine, morphine, oxycodone, tramadol, tapentadol) provide substantial pain relief compared to placebo in postherpetic neuralgia and peripheral neuropathies of different aetiologies for 4–12 weeks. There is insufficient evidence to support or refute the suggestion that these drugs are effective in other neuropathic pain conditions. The safety of opioids with regards to abuse and deaths in the studies analysed cannot be extrapolated to routine clinical care.
A diagnosis of neuropathy can typically be determined through clinical assessment and focused investigation. With technological advances, including significant progress in genomics, the role of nerve biopsy has receded over recent years. However, making a specific and, in some cases, tissue-based diagnosis is essential across a wide array of potentially treatable acquired peripheral neuropathies. When laboratory investigations do not suggest a definitive diagnosis, nerve biopsy remains the final step to ascertain the etiology of the disease. The present review highlights the utility of nerve biopsy in confirming a diagnosis, while further illustrating the importance of a tissue-based diagnosis in relation to treatment strategies, particularly when linked to long-term immunosuppressive therapies,
Background:
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS) for which several new treatment options were recently introduced. Among them is the monoclonal anti-CD52 antibody alemtuzumab that depletes mainly B cells and T cells in the immune periphery. Considering the ongoing controversy about the involvement of B cells and in particular the formation of B cell aggregates in the brains of progressive MS patients, an in-depth understanding of the effects of anti-CD52 antibody treatment on the B cell compartment in the CNS itself is desirable.
Methods:
We used myelin basic protein (MBP)-proteolipid protein (PLP)-induced experimental autoimmune encephalomyelitis (EAE) in C57BL/6 (B6) mice as B cell-dependent model of MS. Mice were treated intraperitoneally either at the peak of EAE or at 60 days after onset with 200 μg murine anti-CD52 vs. IgG2a isotype control antibody for five consecutive days. Disease was subsequently monitored for 10 days. The antigen-specific B cell/antibody response was measured by ELISPOT and ELISA. Effects on CNS infiltration and B cell aggregation were determined by immunohistochemistry. Neurodegeneration was evaluated by Luxol Fast Blue, SMI-32, and Olig2/APC staining as well as by electron microscopy and phosphorylated heavy neurofilament serum ELISA.
Results:
Treatment with anti-CD52 antibody attenuated EAE only when administered at the peak of disease. While there was no effect on the production of MP4-specific IgG, the treatment almost completely depleted CNS infiltrates and B cell aggregates even when given as late as 60 days after onset. On the ultrastructural level, we observed significantly less axonal damage in the spinal cord and cerebellum in chronic EAE after anti-CD52 treatment.
Conclusion:
Anti-CD52 treatment abrogated B cell infiltration and disrupted existing B cell aggregates in the CNS.